Azenta (AZTA) 10-Q 16 May 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	6 Months Ended
	Mar. 31, 2022	May 13, 2022
Cover [Abstract]
Entity Central Index Key	0000933974
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-25434
Entity Registrant Name	AZENTA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3040660
Entity Address, Address Line One	15 Elizabeth Drive
Entity Address, City or Town	Chelmsford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01824
City Area Code	978
Local Phone Number	262-2400
Title of 12(b) Security	Common Stock, $0.01 par value
Entity Listing, Par Value Per Share	$ 0.01
Trading Symbol	AZTA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,988,765
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Current assets
Cash and cash equivalents	$ 1,936,291	$ 227,427
Marketable securities	816,512	81
Accounts receivable, net of allowance for expected credit losses ($4,622 and $4,318, respectively)	137,578	119,877
Inventories	77,752	60,398
Prepaid expenses and other current assets	74,961	58,198
Current assets held for sale		311,385
Total current assets	3,043,094	777,366
Property, plant and equipment, net	150,426	130,719
Long-term marketable securities	260,220	3,598
Long-term deferred tax assets	1,816	10,043
Goodwill	467,746	469,356
Intangible assets, net	170,507	186,534
Other assets	65,237	58,068
Non-current assets held for sale		183,828
Total assets	4,159,046	1,819,512
Current liabilities
Accounts payable	35,868	42,360
Deferred revenue	30,700	25,724
Accrued warranty and retrofit costs	2,491	2,330
Accrued compensation and benefits	41,708	33,183
Accrued restructuring costs	183	304
Accrued income taxes payable	430,650	8,711
Accrued expenses and other current liabilities	76,363	103,537
Current liabilities held for sale		128,939
Total current liabilities	617,963	345,088
Long-term debt		49,677
Long-term tax reserves	2,023	1,973
Long-term deferred tax liabilities	17,502	13,030
Long-term pension liabilities	720	705
Long-term operating lease liabilities	48,698	45,088
Other long-term liabilities	7,164	6,173
Non-current liabilities held for sale		32,444
Total liabilities	694,070	494,178
Commitments and contingencies (Note 16)
Stockholders' Equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value - 125,000,000 shares authorized, 88,445,490 shares issued and 74,983,621 shares outstanding at March 31, 2022, 87,808,922 shares issued and 74,347,053 shares outstanding at September 30, 2021	885	878
Additional paid-in capital	1,986,796	1,976,112
Accumulated other comprehensive income	(7,398)	19,351
Treasury stock, at cost - 13,461,869 shares	(200,956)	(200,956)
Retained earnings (accumulated deficit)	1,685,649	(470,051)
Total stockholders' equity	3,464,976	1,325,334
Total liabilities and stockholders' equity	$ 4,159,046	$ 1,819,512

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Allowance for expected credit losses	$ 4,622	$ 4,318
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	88,445,490	87,808,922
Common stock, shares outstanding	74,983,621	74,347,053
Treasury Stock, Shares [Abstract]
Treasury stock, shares	13,461,869	13,461,869

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenue
Total revenue	$ 145,544	$ 129,535	$ 285,196	$ 247,677
Cost of revenue
Total cost of revenue	74,719	71,635	147,327	132,442
Gross profit	70,825	57,900	137,869	115,235
Operating expenses
Research and development	6,896	5,236	13,381	10,324
Selling, general and administrative	68,515	61,892	129,226	113,823
Restructuring charges	122	92	295	53
Total operating expenses	75,533	67,220	142,902	124,200
Operating loss	(4,708)	(9,320)	(5,033)	(8,965)
Interest income	3,076	18	3,111	94
Interest expense	(1,555)	(452)	(2,010)	(1,008)
Loss on extinguishment of debt	(632)		(632)
Other income (expenses), net	(1,170)	108	(2,248)	1,389
Loss before income taxes	(4,989)	(9,646)	(6,812)	(8,490)
Income tax benefit	(3,173)	(2,310)	(7,853)	(3,860)
(Loss) income from continuing operations	(1,816)	(7,336)	1,041	(4,630)
Income from discontinued operations, net of tax	2,121,690	31,084	2,162,152	54,406
Net income	$ 2,119,874	$ 23,748	$ 2,163,193	$ 49,776
Basic net income per share:
(Loss) income from continuing operations (in dollars per share)	$ (0.02)	$ (0.10)	$ 0.01	$ (0.06)
Income from discontinued operations, net of tax (in dollars per share)	28.31	0.42	28.90	0.73
Basic net income per share (in dollars per share)	28.28	0.32	28.91	0.67
Diluted net income per share:
(Loss) income from continuing operations (in dollars per share)	(0.02)	(0.10)	0.01	(0.06)
Income from discontinued operations, net of tax (in dollars per share)	28.31	0.42	28.77	0.73
Diluted net income per share (in dollars per share)	$ 28.28	$ 0.32	$ 28.79	$ 0.67
Weighted average shares used in computing net income per share:
Basic (in shares)	74,958	74,265	74,823	74,142
Diluted (in shares)	74,958	74,265	75,145	74,142
Products
Revenue
Total revenue	$ 49,449	$ 46,233	$ 95,318	$ 87,695
Cost of revenue
Total cost of revenue	24,953	22,787	49,475	45,580
Services
Revenue
Total revenue	96,095	83,302	189,878	159,982
Cost of revenue
Total cost of revenue	$ 49,766	$ 48,848	$ 97,852	$ 86,862

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 2,119,874	$ 23,748	$ 2,163,193	$ 49,776
Other comprehensive income, net of tax:
Foreign currency translation reclassification adjustments included in income from discontinued operation (Note 2)	(16,567)		(16,567)
Net investment hedge currency translation adjustment	10,673		10,673
Foreign currency translation adjustments	(22,431)	(12,547)	(17,630)	717
Unrealized loss on marketable securities, net of tax effects of $0, $0 fiscal years 2022 and 2021	(3,306)		(3,306)
Actuarial gains, net of tax effects of $20 and $21 during the three and six months ended March 31, 2022, ($4) and $1 during the three and six months ended March 31, 2021	84	39	81	1
Total other comprehensive income, net of tax	(31,547)	(12,508)	(26,749)	718
Comprehensive income	$ 2,088,327	$ 11,240	$ 2,136,444	$ 50,494

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Actuarial gains (losses)	$ 20	$ 4	$ 21	$ 1

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net income	$ 2,163,193	$ 49,776
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	26,005	31,543
Stock-based compensation	7,230	14,191
Amortization of premium on marketable securities and deferred financing costs	66	113
Deferred income taxes	11,054	(10,161)
Loss on extinguishment of debt	632
(Gain) loss on disposals of property, plant and equipment	(30)	51
Gain on divestiture, net of tax	(2,130,351)
Adjustment to the gain on divestiture of semiconductor cryogenics business, net of tax		948
Fees paid stemming from divestiture	(52,461)
Changes in operating assets and liabilities, net of acquisitions and divestiture:
Accounts receivable	(456)	(35,033)
Inventories	(55,033)	(11,301)
Prepaid expenses and other assets	(48,891)	3,157
Accounts payable	(7,906)	14,136
Deferred revenue	5,215	4,659
Accrued warranty and retrofit costs	(198)	(261)
Accrued compensation and tax withholdings	10,875	(5,371)
Accrued restructuring costs	(113)	(124)
Accrued expenses and other liabilities	15,430	21,619
Net cash (used in) provided by operating activities	(55,739)	77,942
Cash flows from investing activities
Purchases of property, plant and equipment	(44,326)	(25,531)
Purchases of technology intangibles	(4,000)
Purchases of marketable securities	(1,074,428)	(75)
Sales of marketable securities	3,710	25
Proceeds from divestiture, net of cash transferred	2,927,245
Adjustment to proceeds from divestiture of semiconductor cryogenics business		(1,802)
Net cash provided by (used in) investing activities	1,808,201	(27,383)
Cash flows from financing activities
Proceeds from issuance of common stock	3,461	2,583
Principal payments on debt	(49,725)	(414)
Payments of finance leases	(312)	(638)
Payment for contingent consideration related to acquisition	(9,400)
Common stock dividends paid	(7,494)	(14,856)
Net cash used in financing activities	(63,470)	(13,325)
Effects of exchange rate changes on cash and cash equivalents	(25,372)	6,051
Net increase in cash, cash equivalents and restricted cash	1,663,620	43,285
Cash, cash equivalents and restricted cash, beginning of period	285,333	302,526
Cash, cash equivalents and restricted cash, end of period	$ 1,948,953	$ 345,811

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents of continuing operations	$ 1,936,291	$ 227,427
Cash and cash equivalents included in assets held for sale		45,000
Short-term restricted cash included in prepaid expenses and other current assets	3,567	7,145
Long-term restricted cash included in other assets	9,095	5,761
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 1,948,953	$ 285,333	$ 345,811
Restricted Cash, Current, Statement of Financial Position	Prepaid expenses and other current assets		Prepaid expenses and other current assets
Restricted Cash, Noncurrent, Statement of Financial Position	Other assets		Other assets

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Total
Beginning Balance at Sep. 30, 2020	$ 873	$ 1,942,850	$ 21,919	$ (551,072)	$ (200,956)	$ 1,213,614
Beginning Balance (in shares) at Sep. 30, 2020	87,293,710
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under restricted stock and purchase plans, net	$ 5	2,578				2,583
Shares issued under restricted stock and purchase plans, net (in shares)	461,956
Stock-based compensation		14,191				14,191
Common stock dividends declared				(14,856)		(14,856)
Foreign currency translation adjustments			717			717
Actuarial loss, net of tax effects			1			1
Net income				49,776		49,776
Ending Balance at Mar. 31, 2021	$ 878	1,959,619	22,637	(516,152)	(200,956)	1,266,026
Ending Balance (in shares) at Mar. 31, 2021	87,755,666
Beginning Balance at Dec. 31, 2020	$ 877	1,949,556	35,145	(532,468)	(200,956)	1,252,154
Beginning Balance (in shares) at Dec. 31, 2020	87,672,132
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under restricted stock and purchase plans, net	$ 1	2,582				2,583
Shares issued under restricted stock and purchase plans, net (in shares)	83,534
Stock-based compensation		7,481				7,481
Common stock dividends declared				(7,432)		(7,432)
Foreign currency translation adjustments			(12,547)			(12,547)
Actuarial loss, net of tax effects			39			39
Net income				23,748		23,748
Ending Balance at Mar. 31, 2021	$ 878	1,959,619	22,637	(516,152)	(200,956)	1,266,026
Ending Balance (in shares) at Mar. 31, 2021	87,755,666
Beginning Balance at Sep. 30, 2021	$ 878	1,976,112	19,351	(470,051)	(200,956)	$ 1,325,334
Beginning Balance (in shares) at Sep. 30, 2021	87,808,922					74,347,053
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under restricted stock and purchase plans, net	$ 7	3,455				$ 3,462
Shares issued under restricted stock and purchase plans, net (in shares)	641,161
Stock-based compensation		7,229				7,229
Common stock dividends declared				(7,493)		(7,493)
Net investment hedge currency translation adjustment			10,673			10,673
Foreign currency translation reclassification adjustments included in income from discontinued operation (Note 2)			(16,567)			(16,567)
Foreign currency translation adjustments			(17,630)			(17,630)
Changes in unrealized gains on marketable securities, net of tax			(3,306)			(3,306)
Actuarial loss, net of tax effects			81			81
Net income				2,163,193		2,163,193
Ending Balance at Mar. 31, 2022	$ 885	1,986,796	(7,398)	1,685,649	(200,956)	$ 3,464,976
Ending Balance (in shares) at Mar. 31, 2022	88,450,083					74,983,621
Beginning Balance at Dec. 31, 2021	$ 884	1,977,571	24,149	(434,225)	(200,956)	$ 1,367,423
Beginning Balance (in shares) at Dec. 31, 2021	88,375,410
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under restricted stock and purchase plans, net	$ 1	3,460				3,461
Shares issued under restricted stock and purchase plans, net (in shares)	74,673
Stock-based compensation		5,765				5,765
Net investment hedge currency translation adjustment			10,673			10,673
Foreign currency translation reclassification adjustments included in income from discontinued operation (Note 2)			(16,567)			(16,567)
Foreign currency translation adjustments			(22,431)			(22,431)
Changes in unrealized gains on marketable securities, net of tax			(3,306)			(3,306)
Actuarial loss, net of tax effects			84			84
Net income				2,119,874		2,119,874
Ending Balance at Mar. 31, 2022	$ 885	$ 1,986,796	$ (7,398)	$ 1,685,649	$ (200,956)	$ 3,464,976
Ending Balance (in shares) at Mar. 31, 2022	88,450,083					74,983,621

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Dividend declared per share (in dollars per share)		$ 0.10	$ 0.10	$ 0.10
Actuarial losses, tax	$ 3	$ (4)	$ 0	$ 5

Nature of Operation

Nature of Operation	6 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operation	1. Nature of Operation Azenta, Inc. (“Azenta”, or the “Company”) is a leading global provider of life science sample exploration and management solutions for the life sciences market. The Company supports its customers from research to clinical development with its sample management, automated storage, and genomic services expertise to help bring impactful therapies to market faster. Discontinued Operations In the fourth quarter of fiscal year 2021, the Company entered into a definitive agreement to sell its semiconductor automation business to Thomas H. Lee Partners, L.P. (“THL”). The Company determined that the semiconductor automation business met the “held for sale” criteria and the “discontinued operations” criteria in accordance with Financial Accounting Standard Boards (“FASB”) Accounting Standards Codification (“ASC”) 205, Presentation of Financial Statements On February 1, 2022, the Company completed the sale of the semiconductor automation business for $2.9 billion in cash, subject to working capital and other customary adjustments. Net cash proceeds from the sale are expected to be $2.5 billion, after deducting estimated taxes payable and other items, such as closing costs. Risks and Uncertainties The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its of new technological innovations, risk of disruption in its supply chain, the implementation of tariffs and export controls, dependence on key personnel, protection of proprietary technology, and compliance with domestic and foreign regulatory authorities and agencies. T . The Company has followed government guidance in each region and has implemented the U.S. Centers for Disease Control and Prevention social distancing guidelines and other best practices to protect the health and safety of the Company’s employees. The COVID-19 pandemic has not had a substantial negative impact on the Company’s financial results and a portion of this impact has been mitigated by the Company’s realignment of resources to satisfy incremental orders related to virus research and vaccine development and commercialization. Future impacts on the Company’s financial results are not fully determinable, as the full impact of the pandemic on the economy and markets which the Company serves is as yet unknown, but will be dependent, in part, on future variants of the virus and vaccine effectiveness against these variants and new or prolonged government responses to the pandemic. The Company’s financial results will also depend on variables including reduced demand from its customers, the degree that the supply chain may be constrained which could impact its delivery of products and services and the potential negative impact on its operations if there is an outbreak among the Company’s employees, as well as the amount of incremental demand caused by research and treatments in the areas of COVID-19 or related threats. ​ ​ ​ ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of the Company and its majority-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The Company applies the equity method of accounting to investments that provide it with the ability to exercise significant influence over the entities in which it lacks controlling financial interest and is not a primary beneficiary. In the opinion of the Company, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2022, and its results of operations for the three months and six months ended March 31, 2022, and 2021, and cash flows for the six months ended March 31, 2022, and 2021. The consolidated balance sheet at September 30, 2021 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission for the fiscal year ended September 30, 2021 (the “2021 Annual Report on Form 10-K”). The accompanying Consolidated Balance Sheet as of September 30, 2021 was derived from the audited annual consolidated financial statements as of the period then ended. Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and record changes in estimates in the period they occur and become known. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition, sales, expenses, reserves and allowances, manufacturing and employee-related amounts, will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. ​ Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expenses), net” in the Company’s Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $1.2 million and $0.4 million during the three months ended March 31, 2022 and 2021, respectively. Net foreign currency transaction and remeasurement losses were $3.2 million and gains were $0.4 million during the six months ended March 31, 2022 and 2021, respectively. The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of all of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income” in the Company’s Consolidated Balance Sheets and presented as a component of comprehensive income in the Company’s Consolidated Statements of Comprehensive Income. The semiconductor automation business had foreign operations which had a cumulative translation adjustment balance of $16.6 million at the date of disposal. This amount was removed from accumulated other comprehensive income during the three months ended March 31, 2022, included in the gain on the sale of the semiconductor automation business. As a result, the Company presented a $16.6 million reclassification adjustment in other comprehensive income for the period. ​ Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than U.S. dollars. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expenses), net” in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three and six months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2022 2021 2022 2021 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ 1,125 ​ $ (5,173) ​ $ 1,054 ​ $ (6,335) ​ ​ The fair values of the forward contracts are recorded in the accompanying unaudited Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts. Hedging Activities During the three months ended March 31, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the United States dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately $1.03 billion for approximately €915 million at a weighted average interest rate of approximately 1.196% . The designated notional amount is $960 million and the actual interest rate is 1.283% . 1.283% was in the range of the market value for that day and is the true interest rate on the notional amount. This cross-currency swap agreement expires in February 2023. We have designated the cross-currency swap as a hedge of net investments against one of our Euro denominated subsidiaries which requires an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap, the Company will deliver a notional amount of €852 million and receive a notional amount of $960 million at an exchange rate of 1.1261 . This cross-currency swap is marked to market at each reporting period, representing the fair values of the cross-currency swap and any changes in fair value are recognized as a component of Accumulated other comprehensive items, net, on the Statements of Comprehensive Income. Interest accrued on the cross-currency swap is recorded within Interest Income on the Consolidated Statements of Operations. For the three and six months ended March 31, 2022, the Company recorded a gain of $10.7 million to Accumulated other comprehensive income and recorded interest income of $2.1 million on this instrument. Fair Value Measurements The Company measures certain financial assets and liabilities, including cash equivalents, available for sale securities, accounts receivable, accounts payable, and derivative instruments at fair value. FASB ASC 820, Fair Value Measurement and Disclosures Accounts Receivable, Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in "Revenue" in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the accompanying unaudited Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the accompanying unaudited Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the accompanying unaudited Consolidated Balance Sheets. Recently Issued Accounting Pronouncements In November 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in fiscal 2023. The Company is evaluating the effect of adopting this new accounting guidance. ​ In March 2020, the FASB issued ASU 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01 , Reference Rate Reform (Topic 848): Scope . The amendments provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The provisions of the amendments are only available until December 31, 2022, when the reference rate replacement activity is expected to be completed. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements and related disclosures. ​ Recently Adopted Accounting Pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . ASU 2021-08 requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the guidance during the first quarter of fiscal year 2022 . There is no accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The amendments in this ASU represent changes to clarify certain ASCs, correct unintended application of guidance, or make minor improvements to certain ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. The amendments in this ASU should be applied retrospectively. This ASU will not affect the Company's consolidated financial statements. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s disclosure to the consolidated financial statements. In August 2018, the FASB issued ASU 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans , which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The amendments require additional disclosure for the weighted-average interest crediting rates, a narrative description of the reasons for significant gains and losses, and an explanation of any other significant changes in the benefit obligation or plan assets. The amendment removes disclosure requirements for accumulated other comprehensive income expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. The ASU is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The ASU does not amend the interim disclosure requirements of ASC 715-20. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) , which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 clarifying and amending existing guidance. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. Other For further information with regard to the Company’s significant accounting policies, please refer to Note 2 “Summary of Significant Accounting Policies” to the Company’s consolidated financial statements included in the 2021 Annual Report on Form 10-K. ​ ​ ​

Discontinued Operations

Discontinued Operations	6 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. Discontinued Operations Disposition of Semiconductor Automation Business On September 20, 2021, the Company entered into a definitive agreement to sell its semiconductor automation business to THL. On February 1, 2022, the Company completed the sale of the semiconductor automation business for $2.9 billion in cash, subject to working capital and other customary adjustments. Net proceeds from the sale are expected to be $2.5 billion, after excluding estimated taxes payable. Net income from discontinued operations for March 31, 2022 is inclusive of the gain on sale of $2.6 billion. As part of the transaction, the Company recorded an $18.1 million liability related to retention bonuses and cash settled stock based awards for former employees of the Company that were conveyed with the transaction. The Company will remit payment to THL during fiscal 2023, at the end of the retention period which THL will directly remit to the respective individuals. The semiconductor automation business is comprised of the Semiconductor Solution Group segment. Following the completion of the sale, the Company no longer serves the semiconductor market. In connection with the closing of the sale, the Company and THL entered into a transition services agreement, to which both the Company and THL will provide each other with certain transition services related to finance and accounting, information technology, human resources, compliance, facilities, legal and research and development support, for time periods ranging from three . In addition, the Company entered into two separate lease agreements for leases back to the Company for portions of the facilities that have served as its corporate headquarters in Chelmsford, Massachusetts, and were sold to THL as part of the sale agreement. Each lease provides for a term of 24 months , which may be terminated earlier by the Company upon 90 days ’ notice to THL. The transition services agreement and lease agreements approximate fair value and there is no material impact to the Company’s results. During the fourth quarter of fiscal 2021, the Company determined that the semiconductor automation business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results are reflected in the Company’s financial statements as a discontinued operation, and assets and liabilities were classified as assets and liabilities held for sale. The following table presents the financial results of discontinued operations with respect to the semiconductor automation business (in thousands). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ Six Months Ended March 31, ​ ​ 2022 ​ 2021 ​ ​ 2022 ​ 2021 Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Products ​ $ 56,722 ​ $ 144,136 ​ ​ $ 244,962 ​ $ $ 262,290 Services ​ ​ 4,038 ​ ​ 12,915 ​ ​ ​ 19,468 ​ ​ 26,122 Total revenue ​ ​ 60,760 ​ ​ 157,051 ​ ​ ​ 264,430 ​ ​ 288,412 Cost of revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Products ​ ​ 33,568 ​ ​ 82,727 ​ ​ ​ 141,165 ​ ​ 151,504 Services ​ ​ 2,850 ​ ​ 4,950 ​ ​ ​ 11,159 ​ ​ 11,741 Total cost of revenue ​ ​ 36,418 ​ ​ 87,677 ​ ​ ​ 152,324 ​ ​ 163,245 Gross profit ​ ​ 24,342 ​ ​ 69,374 ​ ​ ​ 112,106 ​ ​ 125,167 Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ ​ 4,746 ​ ​ 11,708 ​ ​ ​ 18,486 ​ ​ 22,702 Selling, general and administrative ​ ​ 7,466 ​ ​ 17,841 ​ ​ ​ 30,142 ​ ​ 31,940 Restructuring charges ​ ​ - ​ ​ (1) ​ ​ ​ - ​ ​ 126 Total operating expenses ​ ​ 12,212 ​ ​ 29,548 ​ ​ ​ 48,628 ​ ​ 54,768 Operating income ​ ​ 12,130 ​ ​ 39,826 ​ ​ ​ 63,478 ​ ​ 70,399 Other income, net ​ ​ ​ ​ ​ (87) ​ ​ ​ ​ ​ ​ (1,326) Gain on divestiture ​ ​ 2,561,420 ​ ​ - ​ ​ ​ 2,561,374 ​ ​ - Income before income taxes ​ ​ 2,573,550 ​ ​ 39,739 ​ ​ ​ 2,624,852 ​ ​ 69,073 Income tax provision ​ ​ 451,860 ​ ​ 8,655 ​ ​ ​ 462,700 ​ ​ 14,667 Net income from discontinued operations ​ $ 2,121,690 ​ $ 31,084 ​ ​ $ 2,162,152 ​ $ 54,406 ​ ​ On July 1, 2019, the Company sold its semiconductor cryogenics business. During the three and six months ended March 31, 2021, the Company recorded a $1.3 million negative working capital adjustment to the gain on divestiture that was previously recorded in the fourth fiscal quarter of 2019. This adjustment is shown within other income (loss), net within the income statement for the semiconductor automation business. The following table presents the significant non-cash items and capital expenditures for the discontinued operations with respect to the semiconductor automation business that are included in the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ 2022 ​ 2021 ​ ​ ​ 2022 ​ 2021 Depreciation and amortization ​ $ - ​ $ 1,677 ​ ​ $ - ​ $ 3,696 Capital expenditures ​ $ 579 ​ $ 904 ​ ​ $ 2,862 ​ $ 2,731 Stock-based compensation ​ $ 3,109 ​ $ 4,088 ​ ​ $ 8,032 ​ $ 5,963 ​ ​ The carrying value of the assets and liabilities of the discontinued operations with respect to the semiconductor automation business on the Consolidated Balance Sheets as of September 30, 2021 was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 45,000 Accounts receivable, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 142,256 Inventories ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 110,735 Other current assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 13,394 Total current assets of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 311,385 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 32,058 Long-term deferred tax assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3,167 Goodwill ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 81,477 Intangibles, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 44,468 Other assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 22,658 Total long-term assets of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 183,828 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts payable ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 68,074 Deferred revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 7,141 Accrued warranty and retrofit costs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 6,081 Accrued compensation and benefits ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 18,144 Accrued Income Taxes ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 11,702 Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 18,014 Total current liabilities of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 129,156 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term tax reserves ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2,356 Long-term deferred tax liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 6,548 Long-term pension liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5,490 Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 15,425 Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2,625 Total long-term liabilities of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 32,444 ​ ​ Acquisition within the Semiconductor Automation Business On April 29, 2021, the Company acquired Precise Automation Inc., a leading developer of collaborative robots and automation subsystems headquartered in Fremont, California. The total cash purchase price for the acquisition was approximately $69.8 million. Precise provides the semiconductor automation business with a product offering and technology portfolio to take advantage of the opportunities in the collaborative robot market. The allocation of the consideration included $38.7 million of technology, $2.5 million of customer relationships, $33.1 million of goodwill, $6.2 million of deferred tax liabilities, and several other assets and liabilities. The Company applied variations of the income approach to estimate the fair values of the intangible assets acquired. The completed technology was valued using excess earnings method and the customer relationships was valued using distributor margin method, both of which have a useful life of 11 years. The intangible assets acquired are amortized over the total weighted average period of 11 years using methods that approximate the pattern in which the economic benefits are expected to be realized. The Company has included the financial results of the acquired operations within income from discontinued operations on its Consolidated Statements of Operations. The goodwill and intangible assets are not The Company did not present a pro forma information summary for its consolidated results of operations because such results were immaterial. ​ During the three months ended March 31, 2022, and prior to the completion of the sale of the semiconductor automation business, the Company exercised an option acquired with the Precise acquisition, to purchase certain technology assets for $4.0 million. The technology assets worth $4.0 million and the option to purchase was deemed to have no fair value at the time of acquisition.

Marketable Securities

Marketable Securities	6 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	4. Marketable Securities The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the accompanying unaudited Consolidated Balance Sheets. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. Unrealized gains and losses are excluded from earnings and reported as a separate component of “accumulated other comprehensive income, net of tax” in the accompanying unaudited Consolidated Balance Sheets until the security is sold or matures. Gains or losses realized from sales of marketable securities are computed based on the specific identification method and recognized as a component of "Other income (expenses), net" in the accompanying unaudited Consolidated Statements of Operations. There were insignificant sales of marketable securities for the three and six months ended March 31, 2022 and 2021. The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized holding gains (losses) on the short-term and long-term marketable securities as of March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value March 31, 2022: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 720,648 ​ $ (1,185) ​ $ 18 $ 719,481 Corporate securities ​ ​ 258,862 ​ ​ (1,899) ​ ​ — ​ ​ 256,963 Municipal securities ​ 100,518 ​ ​ (230) ​ ​ — ​ 100,288 ​ ​ $ 1,080,028 ​ $ (3,314) ​ $ 18 ​ $ 1,076,732 September 30, 2021: ​ ​ ​ ​ ​ Bank certificates of deposits ​ $ 30 ​ $ — ​ $ — ​ $ 30 Corporate securities ​ ​ 3,624 ​ ​ — ​ ​ — ​ ​ 3,624 Other debt securities ​ 25 ​ ​ — ​ ​ — ​ 25 ​ ​ $ 3,679 ​ $ — ​ $ — ​ $ 3,679 ​ ​ The fair values of the marketable securities by contractual maturities at March 31, 2022 are presented below (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ ​ ​ $ 817,223 ​ $ 816,512 Due after one year through five years ​ ​ ​ 259,382 ​ 256,797 Due after five years through ten years ​ ​ ​ ​ — ​ ​ — Due after ten years ​ ​ ​ 3,422 ​ 3,423 Total marketable securities ​ ​ ​ $ 1,080,027 ​ $ 1,076,732 ​ Expected maturities could differ from contractual maturities because the security issuers may have the right to prepay obligations without prepayment penalties. The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value. The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term prospects of the issuer, the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of its amortized cost basis. If the Company believes that an other-than-temporary decline in fair value has occurred, it writes down the investment to its fair value and recognizes the credit loss in earnings and the non-credit loss in accumulated other comprehensive income or loss. Securities in an unrealized loss position as of March 31, 2022 were $939.1 million. There were no securities in an unrealized loss position as of September 30, 2021.

Acquisitions

Acquisitions	6 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Acquisitions	5. Acquisitions The Company recorded the assets acquired and liabilities assumed related to the following acquisitions at their fair values as of the acquisition date, from a market participant’s perspective. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The finalization of the assignment of fair values will be completed within one year after the respective acquisition date. The Company did not present a pro forma information summary for its consolidated results of operations for the acquisitions completed because such results were immaterial. ​ Abeyatech LLC ​ On April 2, 2021, the Company acquired Abeyatech LLC. The Company has included the financial results of the acquired operations within the Life Sciences Products segment. The purchase price includes $9.9 million cash payment and $9.4 million in contingent consideration, at present value, based on the acquired business’ performance for the twelve-month period ending December 31, 2021, subject to customary working capital adjustments and other adjustments. The acquisition enhances the breadth and depth of the Company’s offerings and expands its expertise in the Life Sciences Products segment. The allocation of the consideration included $11.9 million of technology, $4.4 million of goodwill, and several other assets and liabilities for $3.0 million. The weighted useful life of all the intangible assets acquired is 12 years. The goodwill and intangibles are tax deductible . During the three months ended March 31, 2022, the Company paid $10.0 million related to the contingent consideration recorded at the time of acquisition based on the achievement of business performance targets set forth in the purchase agreement. ​ Trans-Hit Biomarkers, Inc. ​ On December 3, 2020, the Company acquired Trans-Hit Biomarkers Inc. (“THB”), a worldwide biospecimen procurement service provider based in Montreal Canada. THB has an extensive collection capability for biospecimens and clinical samples through a worldwide partner network of clinical sites and biobanks. The total cash purchase price of the acquisition was approximately $15.1 million, net of cash acquired. The acquisition enhances the breadth and depth of the Company’s offerings and expands its expertise in the Life Sciences Services segment. The allocation of the consideration included $7.8 million of customer relationships, $9.3 million of goodwill, $2.4 million of deferred tax liabilities, and several other assets and liabilities. The weighted useful life of all intangibles acquired is 11 years . The Company has included the financial results of the acquired operations in the Life Sciences Services segment. The goodwill and intangibles are not tax deductible.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill represents the excess of net book value over the estimated fair value of net tangible and identifiable intangible assets of a reporting unit. Goodwill is tested for impairment annually or more often if impairment indicators are present at the reporting unit level. If events occur or circumstances change that would more likely than not reduce fair values of the reporting units below their carrying values, goodwill will be evaluated for impairment between annual tests. No triggering events indicating goodwill impairment occurred during the six months ended March 31, 2022. Please refer to Note 8, "Goodwill and Intangible Assets" to the Company's consolidated financial statements included in the 2021 Annual Report on Form 10-K for further information on the goodwill impairment testing performed during fiscal year 2021. The changes in the Company’s goodwill by reportable segment since September 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance, at September 30, 2021 ​ 110,138 ​ 359,218 ​ 469,356 Currency translation adjustments ​ (1,643) ​ 33 ​ (1,610) Balance, at March 31, 2022 ​ $ 108,495 ​ $ 359,251 ​ $ 467,746 ​ ​ The components of the Company’s identifiable intangible assets as of March 31, 2022 and September 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ September 30, 2021 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 1,234 ​ $ 1,055 ​ $ 179 ​ $ 1,242 ​ $ 1,002 ​ $ 240 Completed technology ​ 75,373 ​ 35,833 ​ 39,540 ​ 75,527 ​ 32,383 ​ 43,144 Trademarks and trade names ​ 424 ​ 47 ​ 377 ​ 424 ​ 33 ​ 391 Non-competition agreements ​ ​ 681 ​ ​ 344 ​ ​ 337 ​ ​ 681 ​ ​ 249 ​ ​ 432 Customer relationships ​ 253,063 ​ 122,989 ​ 130,074 ​ 253,486 ​ 111,159 ​ 142,327 Other intangibles ​ ​ 240 ​ ​ 240 ​ ​ — ​ ​ 246 ​ ​ 246 ​ ​ — ​ ​ $ 331,015 ​ $ 160,508 ​ $ 170,507 ​ $ 331,606 ​ $ 145,072 ​ $ 186,534 ​ Amortization expense for intangible assets was $7.9 million and $9.4 million, for the three months ended March 31, 2022 and 2021, respectively. Amortization expense for intangible assets was $15.9 million and $18.3 million, for the six months ended March 31, 2022 and 2021, respectively. Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2022, the subsequent four fiscal years and thereafter is as follows (in thousands): ​ ​ ​ ​ 2022 ​ $ 15,937 2023 ​ 30,845 2024 ​ 27,354 2025 ​ 22,574 2026 ​ 19,435 Thereafter ​ 54,362 ​ ​ $ 170,507 ​ ​ ​

Debt and Line of Credit

Debt and Line of Credit	6 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt and Line of Credit	7. Debt and Line of Credit On October 4, 2017, the Company entered into a $200.0 million term loan with the lenders pursuant to the terms of a credit agreement. The term loan was issued at $197.6 million, or 98.8% of its par value, resulting in a discount of $2.4 million, or 1.2%, which represented loan origination fees paid at the closing. The deferred financing costs are accreted over the term of the loan using the effective interest rate method and are included in “Interest expense” in the accompanying unaudited Consolidated Statements of Operations. During the six months ended March 31, 2022, the weighted average stated interest rate paid on all outstanding debt was 2.7%. During the three and six months ended March 31, 2022, the Company incurred aggregate interest expense of $0.1 million and $0.5 million, respectively, in connection with the borrowings, including $0.1 million of deferred financing costs amortization. ​ On February 1, 2022, the Company completed the sale of its semiconductor automation business and used ​

Leases

Leases	6 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	8. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate in North America, Europe, and Asia. Non-real estate leases are primarily related to vehicles and office equipment. Lease expiration dates range between 2022 and 2042. The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ ​ ​ $ 2,389 ​ $ 1,740 ​ $ 4,560 ​ $ 3,444 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ ​ ​ 54 ​ ​ 250 ​ ​ 129 ​ ​ 561 ​ Interest on lease liabilities ​ ​ ​ ​ 2 ​ ​ 6 ​ ​ 5 ​ ​ 23 ​ Total finance lease costs ​ ​ ​ ​ 56 ​ ​ 256 ​ ​ 134 ​ ​ 584 ​ Variable lease costs ​ ​ ​ ​ 755 ​ ​ 457 ​ ​ 1,272 ​ ​ 863 ​ Short-term lease costs ​ ​ ​ ​ 364 ​ ​ 50 ​ ​ 718 ​ ​ 89 ​ Total lease costs ​ ​ ​ $ 3,564 ​ $ 2,503 ​ $ 6,684 ​ $ 4,980 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ September 30, 2021 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 53,278 ​ $ 49,650 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 6,113 ​ $ 5,254 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 48,698 ​ ​ 45,088 ​ Total operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 54,811 ​ $ 50,342 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 2,252 ​ $ 2,252 ​ Accumulated amortization ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (2,234) ​ ​ (2,105) ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 18 ​ $ 147 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 44 ​ $ 360 ​ Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (10) ​ ​ (10) ​ Total finance lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 350 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 11.74 ​ ​ 11.33 ​ Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 0.08 ​ ​ 0.53 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 4.05 % ​ 3.90 % Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 4.86 % ​ 4.87 % ​ Supplemental cash flow information related to leases was as follows (in thousands, unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ ​ ​ $ 1,950 ​ $ 1,548 ​ $ 3,599 ​ $ 2,968 ​ Operating cash flows from finance leases ​ ​ ​ ​ 1 ​ ​ 12 ​ ​ 4 ​ ​ 27 ​ Financing cash flows from finance leases ​ ​ ​ ​ 127 ​ ​ 307 ​ ​ 312 ​ ​ 611 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ $ 7,327 ​ $ 549 ​ $ 7,490 ​ $ 4,081 ​ ​ ​ Future lease payments for operating and finance leases as of March 31, 2022 were as follows for the remainder of fiscal year 2022, the subsequent five fiscal years and thereafter (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases ​ Operating Leases ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 4,103 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 7,762 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 6,354 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,910 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,839 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,650 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 34,415 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 34 ​ ​ 70,033 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ (15,222) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 54,811 ​ ​ ​ As of March 31, 2022, the Company does not have significant leases that have not commenced or not recorded in the accompanying unaudited Consolidated Balance Sheets .

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company recorded an income tax benefit of $3.2 million and $7.9 million, respectively during the three and six months ended March 31, 2022. The benefit for the three months ended March 31, 2022, was primarily driven by the benefit on loss from operations during the period. The tax benefit for the six months ended March 31, 2022, was increased by a $4.5 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense. The tax benefit for the six months ended March 31, 2022 was partially offset by a $0.6 million charge to increase the deferred tax liability to reflect a change in the blended state income tax rate that results from the sale of the semiconductor business assets. The Company recorded an income tax benefit of $2.3 million and $3.9 million, respectively during the three and six months ended March 31, 2021. The tax benefit for the three months ended March 31, 2021, was primarily driven by the benefit on loss from operations during the period. The benefit for the six months ended March 31, 2021 was increased by a $2.0 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense, respectively. During March 2021, the United States enacted the American Rescue Plan Act of 2021. The Company evaluated the legislation of these Acts in relation to income taxes and determined that the income tax Acts do not have a material impact on its income tax provision. The Company evaluates the realizability of its deferred tax assets by tax-paying component and assesses the need for a valuation allowance on a quarterly basis. The Company evaluates the profitability of each tax-paying component on a historic cumulative basis and a forward-looking basis while performing this analysis. The Company maintains a U.S. valuation allowance related to the realizability of certain state tax credits and state net operating loss carry-forwards, as well as a valuation allowance against net deferred tax assets on certain foreign tax-paying components as of March 31, 2022. On February 1, 2022, the Company completed the sale of its semiconductor automation business that resulted in a taxable gain primarily recognized in the U.S. During the second quarter of fiscal year 2022, the Company recorded a reduction to its valuation allowance for the utilization of deferred tax assets that were previously expected to expire. The benefit of this valuation allowance reversal was recorded in income from discontinued operations in the amount of The Company maintains liabilities for uncertain tax positions. These liabilities involve judgment and estimation and are monitored based on the best information available. The Company recognizes interest related to unrecognized tax benefits as a component of the income tax provision or benefit. The Company recognized $0.1 million of interest expense related to its uncertain tax positions during the three and the six months ended March 31, 2022. The Company is subject to U.S. federal, state, local and foreign income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company’s interpretation of applicable tax laws in the jurisdictions in which it files. In the normal course of business, the Company is subject to income tax audits in various global jurisdictions in which it operates. The years subject to examination vary for the U.S. and international jurisdictions, with the earliest tax year being 2013. Based on the outcome of these examinations or the expiration of statutes of limitations for specific jurisdictions, it is reasonably possible that the related unrecognized tax benefits could change from those recorded in the Company’s Consolidated Balance Sheets. The Company currently anticipates that it is reasonably possible that the unrecognized tax benefits and accrued interest on those benefits will be reduced by an amount of $0.4 million in the next twelve months due to statute of limitations expirations. These unrecognized tax benefits would impact the effective tax rate if recognized.

Other Balance Sheet Information

Other Balance Sheet Information	6 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Balance Sheet Information	10. Other Balance Sheet Information The following is a summary of accounts receivable at March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ September 30, ​ ​ 2022 2021 Accounts receivable ​ $ 142,200 ​ $ 124,195 ​ Less allowance for expected credit losses ​ (4,622) ​ (4,318) ​ Accounts receivable, net ​ $ 137,578 ​ $ 119,877 ​ ​ The following is a summary of inventories at March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ September 30, ​ ​ 2022 2021 Inventories ​ ​ ​ Raw materials and purchased parts ​ $ 28,546 ​ $ 27,644 ​ Work-in-process ​ 5,885 ​ 4,787 ​ Finished goods ​ 43,321 ​ 27,967 ​ Total inventories ​ $ 77,752 ​ $ 60,398 ​ ​ Reserves for excess and obsolete inventory were $4.4 million and $3.7 million, respectively, at March 31, 2022 and September 30, 2021. At March 31, 2022 and September 30, 2021, the Company had cumulative capitalized direct costs of $24.2 million and $22.7 million, respectively, associated with the development of software for its internal use. As of March 31, 2022, this balance included $6.3 million associated with software assets that are still in the development stage and not yet placed in service. During the six months ended March 31, 2022, the Company capitalized direct costs of $1.6 million associated with the development of software for its internal use. The Company establishes reserves for estimated costs of product warranties based on historical information. Product warranty reserves are recorded at the time product revenue is recognized, and retrofit accruals are recorded at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company. The following is a summary of product warranty and retrofit activity on a gross basis for the three and six months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2022 Balance ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ Accruals ​ Costs Incurred ​ 2022 $ 2,342 ​ $ 539 ​ $ (390) ​ $ 2,491 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2021 Balance ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ March 31, 2020 ​ Accruals ​ Costs Incurred ​ 2021 $ 2,267 ​ $ 167 ​ $ (252) ​ $ 2,182 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2022 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ Accruals ​ Costs Incurred ​ 2022 $ 2,330 ​ $ 1,212 ​ $ (1,051) ​ $ 2,491 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2021 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ March 31, 2020 ​ Accruals ​ Costs Incurred ​ 2021 $ 2,211 ​ $ 813 ​ $ (842) ​ $ 2,182 ​

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 31, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation The Company may issue to eligible employees options to purchase shares of the Company’s stock, restricted stock and other equity incentives which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues shares to participating employees pursuant to an employee stock purchase plan, and stock awards and deferred restricted stock units to its directors in accordance with its director compensation program. The stock-based compensation expense for restricted stock units for continuing operations was $5.2 million and $3.2 million, for the three months ended March 31, 2022 and 2021, respectively. The stock-based compensation expense for restricted stock units for continuing operations was $7.7 million and $7.7 million the six months ended March 31, 2022 and 2021, respectively. The stock-based compensation expense for employee stock purchase plan for continuing operations was $0.4 million and $0.2 million, for the three months ended March 31, 2022 and 2021. The stock-based compensation expense for employee stock purchase plan for continuing operations was $0.8 million and $0.5 million, for the six months ended March 31, 2022 and 2021. The information included within the remaining note is on a total company basis, and includes amounts related to our discontinued operations. The following table reflects the total stock-based compensation expense recorded during the three and six months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ 2022 2021 2022 2021 Restricted stock units ​ $ 8,058 ​ $ 7,048 ​ $ 15,255 ​ $ 13,192 ​ Employee stock purchase plan ​ 599 ​ 433 ​ 1,293 ​ 999 ​ Total stock-based compensation expense ​ $ 8,657 ​ $ 7,481 ​ $ 16,548 ​ $ 14,191 ​ ​ The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant. For awards that vest based on service conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period. For awards that vest subject to performance conditions, the Company recognizes stock-based compensation expense ratably over the performance period if it is probable that performance condition will be met and adjusted for the probability percentage of achieving the performance goals. The Company makes estimates of stock award forfeitures and the number of awards expected to vest. The Company considers many factors in developing forfeiture estimates, including award types, employee classes and historical experience. Each quarter, the Company assesses the probability of achieving the performance goals. Current estimates may differ from actual results and future changes in estimates. The Company grants restricted stock units that vest over a required service period and/or achievement of certain operating performance goals. Restricted stock units granted with performance goals may also have a required service period following the achievement of all or a portion of the performance goals. The following table reflects restricted stock units, including stock awards, granted during the six months ended March 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time-Based Stock Performance- ​ ​ Total Units ​ Units ​ Grants ​ Based Units Six months ended March 31, 2022 228,468 101,706 16,286 110,476 Six months ended March 31, 2021 329,801 ​ 149,249 14,657 165,895 ​ Time-Based Grants Restricted stock units granted with a required service period typically have three-year vesting schedules in which one-third one-third one-third Stock Grants The stock awards granted to the members of the Company’s Board of Directors include stock awards and deferred restricted stock units. Certain members of the Board of Directors have elected to defer receiving their annual stock awards and related quarterly dividends until they attain a certain age or cease to provide services as the Company’s Board members. Stock awards granted in fiscal years 2022 and 2021 were vested as of the respective grant dates. Performance-Based Grants Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Board of Directors. The criteria for performance-based awards are weighted and have threshold, target and maximum performance goals. Performance-based awards granted in fiscal year 2022, 2021 and 2020 allow participants to earn 100% of the restricted stock units if the Company’s performance meets its target goal for each applicable financial metric, and up to a maximum of 200% if the Company’s performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals will be measured over a three-year period for each year’s awards and at the end of the period to determine the number of units earned by recipients who continue to meet the service requirement. Around the third anniversary of each year’s awards’ grant date, the Company’s Board of Directors determines the number of units earned for participants who continue to meet the service requirements on the vest date. Restricted Stock Unit Activity The following table summarizes restricted stock unit activity for the six months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding at September 30, 2021 1,088,652 ​ $ 47.35 Granted 228,468 ​ ​ 103.31 Vested (208,713) ​ ​ 40.03 Forfeited (553,624) ​ ​ 39.30 Outstanding at March 31, 2022 554,783 ​ ​ 75.14 ​ The weighted average grant date fair value of restricted stock units granted during the three months ended March 31, 2022 and 2021 was $82.34 and $80.09, respectively. The fair value of restricted stock units vested during the three months ended March 31, 2022 and 2021 was $1.9 million and $2.0 million, respectively. The weighted average grant date fair value of restricted stock units granted during the six months ended March 31, 2022 and 2021 was $103.31 and $70.18, respectively. The fair value of restricted stock units vested during the six months ended March 31, 2022 and 2021 was $66.7 million and $27.9 million, respectively. During the six months ended March 31, 2022 and 2021, the Company remitted $25.1 million and $9.7 million, respectively, collected from employees to satisfy their tax obligations as a result of share issuances. Such proceeds collected and remitted were insignificant during the three months ended March 31, 2022 and 2021. As of March 31, 2022, the unrecognized compensation cost that are expected to vest is $29.0 million and will be recognized over an estimated weighted average service period of approximately 1.9 years. Employee Stock Purchase Plan The Company maintains an employee stock purchase plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual offering period, whichever is lower. There were 51,133 and 58,124 shares, respectively, purchased by employees under the employee stock purchase plan during the six months ended March 31, 2022 and 2021.

Earnings per Share

Earnings per Share	6 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Earnings per Share	12. Earnings per Share The calculations of basic and diluted net income per share and basic and diluted weighted average shares outstanding are as follows for the three and six months ended March 31, 2022 and 2021 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2022 2021 2022 2021 (Loss) income from continuing operations ​ $ (1,816) ​ $ (7,336) ​ $ 1,041 ​ $ (4,630) ​ Income from discontinued operations, net of tax ​ 2,121,690 ​ 31,084 ​ 2,162,152 ​ 54,406 ​ Net income ​ $ 2,119,874 ​ $ 23,748 ​ $ 2,163,193 ​ $ 49,776 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic earnings per share ​ 74,958 ​ 74,265 ​ 74,823 ​ 74,142 ​ Dilutive restricted stock units ​ — ​ — ​ 322 ​ — ​ Weighted average common shares outstanding used in computing diluted earnings per share ​ 74,958 ​ 74,265 ​ 75,145 ​ 74,142 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income per share: ​ ​ ​ ​ ​ (Loss) income from continuing operations ​ $ (0.02) ​ $ (0.10) ​ $ 0.01 ​ $ (0.06) ​ Income from discontinued operations, net of tax ​ 28.31 ​ 0.42 ​ 28.90 ​ 0.73 ​ Basic net income per share ​ $ 28.28 ​ $ 0.32 ​ $ 28.91 ​ $ 0.67 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income per share: ​ ​ ​ ​ ​ (Loss) income from continuing operations ​ $ (0.02) ​ $ (0.10) ​ $ 0.01 ​ $ (0.06) ​ Income from discontinued operations, net of tax ​ 28.31 ​ 0.42 ​ 28.77 ​ 0.73 ​ Diluted net income per share ​ $ 28.28 ​ $ 0.32 ​ $ 28.79 ​ $ 0.67 ​ ​ During the six months ended March 31, 2022, restricted stock units of 59,513 were excluded from the computation of diluted earnings per share as their effect would be antidilutive to earnings per share for continuing operations based on the treasury stock method.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	13. Revenue from Contracts with Customers Disaggregated Revenue The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the three and six months ended March 31, 2022 and 2021(in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ Six months ended March 31, ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ ​ 2021 ​ Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 53,615 ​ $ 52,355 ​ $ 103,493 ​ $ 97,899 ​ Sample Repository Solutions ​ ​ ​ 26,929 ​ ​ 22,191 ​ ​ 52,805 ​ ​ 42,724 ​ Genomic Services ​ ​ ​ 65,000 ​ ​ 54,989 ​ ​ 128,898 ​ ​ 107,054 ​ Total ​ ​ $ 145,544 ​ $ 129,535 ​ $ 285,196 ​ $ 247,677 ​ ​ ​ Contract Balances Accounts Receivable, Net. before payment is due. Accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of probable credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance for expected credit losses based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information through the payment periods. Accounts receivable, net were $137.6 million and $119.9 million at March 31, 2022 and September 30, 2021, respectively. Contract Assets. ​ Contract Liabilities. ​ Remaining Performance Obligations. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2022 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining Performance Obligations ​ $ 41,405 ​ $ 14,300 ​ $ 55,705 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost to Obtain and Fulfill a Contract The Company capitalizes sales commissions when incurred if they are (i) incremental costs of obtaining a contract, (ii) expected to be recovered and (iii) have an expected amortization period that is greater than one year. As part of the Company’s cumulative effect adjustment, incremental costs associated with obtaining a contract were capitalized and have been classified as deferred commissions within the Company’s Consolidated Balance Sheet. These amounts primarily relate to sales commissions within the Life Sciences segments and are being amortized over a 60-month period, which represents the average period of contract performance. The Company did not capitalize any sales commissions during the six months ended March 31, 2022 as the amount of sales commissions that qualified for capitalization during the reporting period was insignificant. Sales commissions incurred during the reporting period have been expensed as incurred. These costs are recorded within “Selling, general and administrative” expenses on the Company’s Consolidated Statement of Operations. The Company has concluded that none of its costs incurred in fulfillment of customer contracts meet the capitalization criteria. The Company will account for shipping and handling activities as fulfillment activities and recognize the associated expense when control of the product has transferred to the customer.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment and Geographic Information	14. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company operates in two reportable segments: the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments . The Company previously operated in , our Semiconductor Solutions Group reportable segment has been classified as a discontinued operation. Historical information has been adjusted to reflect the new reportable segments. The sale of the semiconductor automation business was completed on February 1, 2022. The Life Sciences Products segment provides automated cold sample management systems for compound and biological sample storage, equipment for sample preparation and handling, consumables, and instruments, that help customers manage samples throughout their research discovery and development workflows. The segment’s product offerings include automated cold storage systems, cryogenic storage systems, consumables and instruments and the associated services business for these products. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, as well as sample-based laboratory services to advance scientific research and support drug development. The segment’s service offerings include sample storage, genomic sequencing, gene synthesis, laboratory processing services, laboratory analysis, biospecimen procurement services and other support services which are provided to a wide range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories and research institutes. Our Sample Repository Solutions business is a global leader in sample and material storage and management and provides a full suite of reliable cold and ultra-cold chain solutions. The Company considers adjusted operating income, which excludes charges related to amortization of completed technology, the acquisition accounting impact on inventory contracts acquired, restructuring related charges and other special charges, such as impairment losses, as the primary performance metric when evaluating the business. The following is the summary of the financial information for the Company’s reportable segments for the three and six months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Revenue: ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 53,615 ​ $ 52,355 ​ ​ 103,487 ​ ​ 97,899 ​ Life Sciences Services ​ ​ 91,929 ​ 77,180 ​ 181,709 ​ 149,778 ​ Total revenue ​ ​ $ 145,544 ​ $ 129,535 ​ $ 285,196 ​ $ 247,677 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 5,288 ​ $ 7,248 ​ ​ 9,679 ​ ​ 11,431 ​ Life Sciences Services ​ ​ 4,856 ​ 5,614 ​ 12,740 ​ 12,542 ​ Reportable segment adjusted operating income ​ ​ ​ 10,144 ​ ​ 12,862 ​ ​ 22,419 ​ ​ 23,973 ​ Amortization of completed technology ​ ​ ​ 1,840 ​ ​ 2,021 ​ ​ 3,613 ​ ​ 4,026 ​ Amortization of other intangible assets ​ ​ ​ 6,047 ​ ​ 7,356 ​ ​ 12,319 ​ ​ 14,261 ​ Restructuring charges ​ ​ ​ 122 ​ ​ 92 ​ ​ 295 ​ ​ 53 ​ Tariff adjustment ​ ​ ​ (486) ​ ​ 5,497 ​ ​ (486) ​ ​ 5,497 ​ Other unallocated corporate expenses ​ ​ ​ 7,329 ​ ​ 7,216 ​ ​ 11,711 ​ ​ 9,101 ​ Total operating loss ​ ​ ​ (4,708) ​ ​ (9,320) ​ ​ (5,033) ​ ​ (8,965) ​ Interest income ​ ​ ​ 3,076 ​ ​ 18 ​ ​ 3,111 ​ ​ 94 ​ Interest expense ​ ​ ​ (1,555) ​ ​ (452) ​ ​ (2,010) ​ ​ (1,008) ​ Loss on extinguishment of debt ​ ​ ​ (632) ​ ​ — ​ ​ (632) ​ ​ — ​ Other income (expenses), net ​ ​ ​ (1,170) ​ ​ 108 ​ ​ (2,248) ​ ​ 1,389 ​ Loss before income taxes ​ ​ $ (4,989) ​ $ (9,646) ​ $ (6,812) ​ $ (8,490) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ Life Sciences Products ​ ​ Life Sciences Services ​ ​ Total ​ ​ ​ ​ March 31, 2022 ​ ​ $ 288,902 ​ $ 825,881 ​ $ 1,114,783 ​ ​ ​ ​ September 30, 2021 ​ ​ 278,769 ​ ​ 780,238 ​ 1,059,007 ​ ​ ​ ​ ​ ​ The following is a reconciliation of the Company’s reportable segments’ segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets as of March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2022 ​ 2021 Segment assets $ 1,114,783 $ 1,059,007 Cash and cash equivalents, restricted cash, and marketable securities ​ 3,025,685 ​ 244,012 Deferred tax assets ​ 1,816 ​ 10,043 Other assets ​ ​ 16,762 ​ ​ 11,237 Assets held for sale ​ — ​ 495,213 Total assets ​ $ 4,159,046 ​ $ 1,819,512 ​ Revenue from external customers is attributed to geographic areas based on locations to which customer orders are shipped. Net revenue by geographic area for the three and six months ended March 31, 2022 and 2021 (in thousands) are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ ​ Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ $ 94,283 ​ $ 79,753 ​ $ 184,366 ​ $ 153,302 ​ ​ Europe ​ ​ 26,554 ​ ​ 29,514 ​ ​ 55,149 ​ ​ 55,403 ​ ​ China ​ ​ 13,757 ​ ​ 11,736 ​ ​ 26,798 ​ ​ 22,791 ​ ​ Asia / Pacific/ Other ​ ​ 10,950 ​ ​ 8,532 ​ ​ 18,883 ​ ​ 16,181 ​ ​ Total ​ $ 145,544 ​ $ 129,535 ​ $ 285,196 ​ $ 247,677 ​ ​ ​ ​ Revenue for the United States comprises 99% of the revenue for North America for the three and six months ended March 31, 2022 and 2021.

Significant Customers

Significant Customers	6 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
Significant Customers	15. Significant Customers The Company had no individual customer that accounted for 10% or more of its consolidated revenue for each of the three and six months ended March 31, 2022 and 2021. There was no customer that accounted for more than 10% of the Company’s accounts receivable balance as of both March 31, 2022 and September 30, 2021.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Tariff Matter In fiscal year 2021, as part of the Company’s continued integration of GENEWIZ, which was acquired in November 2018, the Company initiated a review during first quarter of fiscal year 2021, with the assistance of a third party consultant, of the transaction value that the Company has used to calculate tariffs on inter-company imports of samples shipped from its GENEWIZ business. As a result of the third-party review and in light of a new interpretation surrounding the valuation method used to calculate the estimated transaction value, the Company revised its estimate of the tariffs owed and recorded and as a result recorded a liability of $6.1 million in the second quarter of fiscal 2021. As of March 31, 2022 and September 30, 2021, the accrual was $7.4 million and $7.0 million, respectively, which includes estimates for any additional liability for tariffs owed related to recurring operating activity. During the three months ended March 31, 2022, upon the completion of an independent transfer price study, the Company recorded a benefit of $0.5 million related to the reduction of the accrual for the fiscal years 2016 through 2020. Subsequent to March 31, 2022, the Company submitted a payment in the amount of million to the customs authorities related to the November of 2021 and prior periods. The customs authorities will review the Company’s calculation of tariff for these periods and determine if any further tariffs are owed. The Company does not expect to incur any significant penalties associated with the tariffs. Purchase Commitments At March 31, 2022, the Company had non-cancellable commitments of $97.0 million, including primarily purchase orders for inventory of $76.7 million, information technology related commitments of $16.7 million, and China facility commitments of $3.6 million. Contingencies The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. The Company may also have certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards Vacuum LLC (a member of the Atlas Copco Group) in connection with the Company’s sale of its semiconductor cryogenics business in the fourth quarter of fiscal year 2018. However, as of the date of this report, the Company believes that none of these claims will have a material adverse effect on its consolidated financial position or results of operations. In the third quarter of fiscal year 2020, Edwards asserted claims for indemnification under the definitive agreement relating to alleged breaches of representations and warranties relating to customer warranty claims and inventory. The Company cannot determine the probability of any losses or outcome of these claims including the amount of any indemnifiable losses, if any, resulting from these claims at this time, however, the Company believes that none of these claims will have a material adverse effect on its consolidated financial position or results of operations. If the resolution of these claims results in indemnifiable losses in excess of the applicable indemnification deductibles and indemnification escrow established under the definitive agreement, Edwards would be required to seek recovery under the representation and warranty insurance Edwards obtained in connection with the closing of the transaction. The Company believes that any indemnifiable losses in excess of the applicable deductibles and indemnification escrow established in the definitive agreement would be covered by such insurance. If Edwards is unable to obtain recovery under its insurance, however, it could seek recovery of such indemnifiable losses, if any, directly from the Company’s continuing operation. In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be no assurance that the Company’s assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company’s consolidated financial position or results of operations in particular quarterly or annual periods.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	17. Fair Value Measurement The fair value measurement guidance establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following levels of inputs may be used to measure fair value: ​ Level 1 Inputs: Level 2 Inputs: Level 3 Inputs: The Company measures certain assets, including the cost and equity method investments, at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparable, and discounted cash flow projections. An impairment charge is recorded when the cost of the investment exceeds its fair value and this condition is determined to be other-than-temporary. ​ Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured and recorded at fair value on a recurring basis in the accompanying Consolidated Balance Sheets as of March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ March 31, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2022 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 764,361 ​ $ 764,361 ​ $ — ​ $ — Available-for-sale securities ​ 1,076,732 ​ 517,457 ​ ​ 559,275 ​ — Foreign exchange contracts ​ 130 ​ — ​ 130 ​ — Net Investment Hedge ​ 10,673 ​ — ​ 10,673 ​ — Total Assets ​ $ 1,851,896 ​ $ 1,281,818 ​ $ 570,078 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 734 ​ ​ — ​ ​ 734 ​ ​ — Total Liabilities ​ $ 734 ​ $ — ​ $ 734 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ September 30, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2021 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 21 ​ $ 21 ​ $ — ​ $ — Available-for-sale securities ​ 3,679 ​ — ​ 3,679 ​ — Foreign exchange contracts ​ 153 ​ — ​ 153 ​ — Total Assets ​ $ 3,853 ​ $ 21 ​ $ 3,832 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 165 ​ $ — ​ ​ 165 ​ ​ — Acquisition-related contingent consideration ​ ​ 9,400 ​ ​ — ​ ​ — ​ ​ 9,400 Total Liabilities ​ $ 9,565 ​ $ — ​ $ 165 ​ $ 9,400 ​ ​ Cash Equivalents Cash equivalents consist of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Available-For-Sale Securities Available-for-sale securities primarily consist of municipal securities, bank certificate of deposits and U.S. government backed securities, and as such are classified as Level 1. Investments classified as Level 2 consist of debt securities that are valued using matrix pricing and benchmarking because they are not actively traded. Matrix pricing is a mathematical technique used to value securities by relying on the securities’ relationship to other benchmark quoted prices. Foreign Exchange Contracts Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts. Net Investment Hedge Net investment hedge assets is measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts. Acquisition-related Contingent Consideration Acquisition-related contingent consideration is measured and reported at fair value using the real options method based on the unobservable inputs that are significant to the fair value and classified with Level 3 of the fair value hierarchy. The amount is contingent based on the acquired business’ performance for the twelve-month period ending December 31, 2021. Please refer to Note 5, “Acquisitions” for further detail. Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled. Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis During the three months and six months ended March 31, 2022 and 2021, the Company did not record any material other-than-temporary impairments on financial assets required to be measured at fair value on a nonrecurring basis.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of the Company and its majority-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The Company applies the equity method of accounting to investments that provide it with the ability to exercise significant influence over the entities in which it lacks controlling financial interest and is not a primary beneficiary. In the opinion of the Company, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2022, and its results of operations for the three months and six months ended March 31, 2022, and 2021, and cash flows for the six months ended March 31, 2022, and 2021. The consolidated balance sheet at September 30, 2021 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission for the fiscal year ended September 30, 2021 (the “2021 Annual Report on Form 10-K”). The accompanying Consolidated Balance Sheet as of September 30, 2021 was derived from the audited annual consolidated financial statements as of the period then ended.
Use of Estimates	Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and record changes in estimates in the period they occur and become known. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition, sales, expenses, reserves and allowances, manufacturing and employee-related amounts, will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods.
Foreign Currency Translation	Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expenses), net” in the Company’s Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $1.2 million and $0.4 million during the three months ended March 31, 2022 and 2021, respectively. Net foreign currency transaction and remeasurement losses were $3.2 million and gains were $0.4 million during the six months ended March 31, 2022 and 2021, respectively. The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of all of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income” in the Company’s Consolidated Balance Sheets and presented as a component of comprehensive income in the Company’s Consolidated Statements of Comprehensive Income. The semiconductor automation business had foreign operations which had a cumulative translation adjustment balance of $16.6 million at the date of disposal. This amount was removed from accumulated other comprehensive income during the three months ended March 31, 2022, included in the gain on the sale of the semiconductor automation business. As a result, the Company presented a $16.6 million reclassification adjustment in other comprehensive income for the period.
Derivative Financial Instruments	Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than U.S. dollars. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expenses), net” in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three and six months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2022 2021 2022 2021 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ 1,125 ​ $ (5,173) ​ $ 1,054 ​ $ (6,335) ​ ​ The fair values of the forward contracts are recorded in the accompanying unaudited Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts.
Hedging Activities	Hedging Activities During the three months ended March 31, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the United States dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately $1.03 billion for approximately €915 million at a weighted average interest rate of approximately 1.196% . The designated notional amount is $960 million and the actual interest rate is 1.283% . 1.283% was in the range of the market value for that day and is the true interest rate on the notional amount. This cross-currency swap agreement expires in February 2023. We have designated the cross-currency swap as a hedge of net investments against one of our Euro denominated subsidiaries which requires an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap, the Company will deliver a notional amount of €852 million and receive a notional amount of $960 million at an exchange rate of 1.1261 . This cross-currency swap is marked to market at each reporting period, representing the fair values of the cross-currency swap and any changes in fair value are recognized as a component of Accumulated other comprehensive items, net, on the Statements of Comprehensive Income. Interest accrued on the cross-currency swap is recorded within Interest Income on the Consolidated Statements of Operations. For the three and six months ended March 31, 2022, the Company recorded a gain of $10.7 million to Accumulated other comprehensive income and recorded interest income of $2.1 million on this instrument.
Fair Value Measurements	Fair Value Measurements The Company measures certain financial assets and liabilities, including cash equivalents, available for sale securities, accounts receivable, accounts payable, and derivative instruments at fair value. FASB ASC 820, Fair Value Measurement and Disclosures
Accounts Receivable, Allowance for Expected Credit Losses and Sales Returns	Accounts Receivable, Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in "Revenue" in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers.
Leases	Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the accompanying unaudited Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the accompanying unaudited Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the accompanying unaudited Consolidated Balance Sheets.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in fiscal 2023. The Company is evaluating the effect of adopting this new accounting guidance. ​ In March 2020, the FASB issued ASU 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01 , Reference Rate Reform (Topic 848): Scope . The amendments provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The provisions of the amendments are only available until December 31, 2022, when the reference rate replacement activity is expected to be completed. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements and related disclosures. ​ Recently Adopted Accounting Pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . ASU 2021-08 requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the guidance during the first quarter of fiscal year 2022 . There is no accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The amendments in this ASU represent changes to clarify certain ASCs, correct unintended application of guidance, or make minor improvements to certain ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. The amendments in this ASU should be applied retrospectively. This ASU will not affect the Company's consolidated financial statements. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s disclosure to the consolidated financial statements. In August 2018, the FASB issued ASU 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans , which amends ASC 715 to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The amendments require additional disclosure for the weighted-average interest crediting rates, a narrative description of the reasons for significant gains and losses, and an explanation of any other significant changes in the benefit obligation or plan assets. The amendment removes disclosure requirements for accumulated other comprehensive income expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. The ASU is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The ASU does not amend the interim disclosure requirements of ASC 715-20. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) , which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 clarifying and amending existing guidance. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU.
Other	Other For further information with regard to the Company’s significant accounting policies, please refer to Note 2 “Summary of Significant Accounting Policies” to the Company’s consolidated financial statements included in the 2021 Annual Report on Form 10-K. ​

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Realized gains (losses) on derivatives not designated as hedging instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2022 2021 2022 2021 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ 1,125 ​ $ (5,173) ​ $ 1,054 ​ $ (6,335) ​

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ Six Months Ended March 31, ​ ​ 2022 ​ 2021 ​ ​ 2022 ​ 2021 Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Products ​ $ 56,722 ​ $ 144,136 ​ ​ $ 244,962 ​ $ $ 262,290 Services ​ ​ 4,038 ​ ​ 12,915 ​ ​ ​ 19,468 ​ ​ 26,122 Total revenue ​ ​ 60,760 ​ ​ 157,051 ​ ​ ​ 264,430 ​ ​ 288,412 Cost of revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Products ​ ​ 33,568 ​ ​ 82,727 ​ ​ ​ 141,165 ​ ​ 151,504 Services ​ ​ 2,850 ​ ​ 4,950 ​ ​ ​ 11,159 ​ ​ 11,741 Total cost of revenue ​ ​ 36,418 ​ ​ 87,677 ​ ​ ​ 152,324 ​ ​ 163,245 Gross profit ​ ​ 24,342 ​ ​ 69,374 ​ ​ ​ 112,106 ​ ​ 125,167 Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ ​ 4,746 ​ ​ 11,708 ​ ​ ​ 18,486 ​ ​ 22,702 Selling, general and administrative ​ ​ 7,466 ​ ​ 17,841 ​ ​ ​ 30,142 ​ ​ 31,940 Restructuring charges ​ ​ - ​ ​ (1) ​ ​ ​ - ​ ​ 126 Total operating expenses ​ ​ 12,212 ​ ​ 29,548 ​ ​ ​ 48,628 ​ ​ 54,768 Operating income ​ ​ 12,130 ​ ​ 39,826 ​ ​ ​ 63,478 ​ ​ 70,399 Other income, net ​ ​ ​ ​ ​ (87) ​ ​ ​ ​ ​ ​ (1,326) Gain on divestiture ​ ​ 2,561,420 ​ ​ - ​ ​ ​ 2,561,374 ​ ​ - Income before income taxes ​ ​ 2,573,550 ​ ​ 39,739 ​ ​ ​ 2,624,852 ​ ​ 69,073 Income tax provision ​ ​ 451,860 ​ ​ 8,655 ​ ​ ​ 462,700 ​ ​ 14,667 Net income from discontinued operations ​ $ 2,121,690 ​ $ 31,084 ​ ​ $ 2,162,152 ​ $ 54,406 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ 2022 ​ 2021 ​ ​ ​ 2022 ​ 2021 Depreciation and amortization ​ $ - ​ $ 1,677 ​ ​ $ - ​ $ 3,696 Capital expenditures ​ $ 579 ​ $ 904 ​ ​ $ 2,862 ​ $ 2,731 Stock-based compensation ​ $ 3,109 ​ $ 4,088 ​ ​ $ 8,032 ​ $ 5,963 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 45,000 Accounts receivable, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 142,256 Inventories ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 110,735 Other current assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 13,394 Total current assets of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 311,385 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 32,058 Long-term deferred tax assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3,167 Goodwill ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 81,477 Intangibles, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 44,468 Other assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 22,658 Total long-term assets of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 183,828 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts payable ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 68,074 Deferred revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 7,141 Accrued warranty and retrofit costs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 6,081 Accrued compensation and benefits ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 18,144 Accrued Income Taxes ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 11,702 Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 18,014 Total current liabilities of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 129,156 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term tax reserves ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2,356 Long-term deferred tax liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 6,548 Long-term pension liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5,490 Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 15,425 Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2,625 Total long-term liabilities of discontinued operation ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 32,444 ​

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost and Fair Value, Including Accrued Interest Receivable and Unrealized Holding Gains (Losses) on Short-term and Long-term Marketable Securities	The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized holding gains (losses) on the short-term and long-term marketable securities as of March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value March 31, 2022: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 720,648 ​ $ (1,185) ​ $ 18 $ 719,481 Corporate securities ​ ​ 258,862 ​ ​ (1,899) ​ ​ — ​ ​ 256,963 Municipal securities ​ 100,518 ​ ​ (230) ​ ​ — ​ 100,288 ​ ​ $ 1,080,028 ​ $ (3,314) ​ $ 18 ​ $ 1,076,732 September 30, 2021: ​ ​ ​ ​ ​ Bank certificates of deposits ​ $ 30 ​ $ — ​ $ — ​ $ 30 Corporate securities ​ ​ 3,624 ​ ​ — ​ ​ — ​ ​ 3,624 Other debt securities ​ 25 ​ ​ — ​ ​ — ​ 25 ​ ​ $ 3,679 ​ $ — ​ $ — ​ $ 3,679 ​
Fair Value of Marketable Securities by Contractual Maturity	The fair values of the marketable securities by contractual maturities at March 31, 2022 are presented below (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ ​ ​ $ 817,223 ​ $ 816,512 Due after one year through five years ​ ​ ​ 259,382 ​ 256,797 Due after five years through ten years ​ ​ ​ ​ — ​ ​ — Due after ten years ​ ​ ​ 3,422 ​ 3,423 Total marketable securities ​ ​ ​ $ 1,080,027 ​ $ 1,076,732

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Goodwill by Business Segment	The changes in the Company’s goodwill by reportable segment since September 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance, at September 30, 2021 ​ 110,138 ​ 359,218 ​ 469,356 Currency translation adjustments ​ (1,643) ​ 33 ​ (1,610) Balance, at March 31, 2022 ​ $ 108,495 ​ $ 359,251 ​ $ 467,746 ​
Components of Identifiable Intangible Assets	The components of the Company’s identifiable intangible assets as of March 31, 2022 and September 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ September 30, 2021 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 1,234 ​ $ 1,055 ​ $ 179 ​ $ 1,242 ​ $ 1,002 ​ $ 240 Completed technology ​ 75,373 ​ 35,833 ​ 39,540 ​ 75,527 ​ 32,383 ​ 43,144 Trademarks and trade names ​ 424 ​ 47 ​ 377 ​ 424 ​ 33 ​ 391 Non-competition agreements ​ ​ 681 ​ ​ 344 ​ ​ 337 ​ ​ 681 ​ ​ 249 ​ ​ 432 Customer relationships ​ 253,063 ​ 122,989 ​ 130,074 ​ 253,486 ​ 111,159 ​ 142,327 Other intangibles ​ ​ 240 ​ ​ 240 ​ ​ — ​ ​ 246 ​ ​ 246 ​ ​ — ​ ​ $ 331,015 ​ $ 160,508 ​ $ 170,507 ​ $ 331,606 ​ $ 145,072 ​ $ 186,534
Schedule of Future Amortization Expense	Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2022, the subsequent four fiscal years and thereafter is as follows (in thousands): ​ ​ ​ ​ 2022 ​ $ 15,937 2023 ​ 30,845 2024 ​ 27,354 2025 ​ 22,574 2026 ​ 19,435 Thereafter ​ 54,362 ​ ​ $ 170,507 ​

Leases (Tables)

Leases (Tables)	6 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of leases	The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ ​ ​ $ 2,389 ​ $ 1,740 ​ $ 4,560 ​ $ 3,444 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ ​ ​ 54 ​ ​ 250 ​ ​ 129 ​ ​ 561 ​ Interest on lease liabilities ​ ​ ​ ​ 2 ​ ​ 6 ​ ​ 5 ​ ​ 23 ​ Total finance lease costs ​ ​ ​ ​ 56 ​ ​ 256 ​ ​ 134 ​ ​ 584 ​ Variable lease costs ​ ​ ​ ​ 755 ​ ​ 457 ​ ​ 1,272 ​ ​ 863 ​ Short-term lease costs ​ ​ ​ ​ 364 ​ ​ 50 ​ ​ 718 ​ ​ 89 ​ Total lease costs ​ ​ ​ $ 3,564 ​ $ 2,503 ​ $ 6,684 ​ $ 4,980 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ September 30, 2021 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 53,278 ​ $ 49,650 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 6,113 ​ $ 5,254 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 48,698 ​ ​ 45,088 ​ Total operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 54,811 ​ $ 50,342 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 2,252 ​ $ 2,252 ​ Accumulated amortization ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (2,234) ​ ​ (2,105) ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 18 ​ $ 147 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 44 ​ $ 360 ​ Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (10) ​ ​ (10) ​ Total finance lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 350 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 11.74 ​ ​ 11.33 ​ Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 0.08 ​ ​ 0.53 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 4.05 % ​ 3.90 % Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 4.86 % ​ 4.87 % ​ Supplemental cash flow information related to leases was as follows (in thousands, unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ ​ ​ $ 1,950 ​ $ 1,548 ​ $ 3,599 ​ $ 2,968 ​ Operating cash flows from finance leases ​ ​ ​ ​ 1 ​ ​ 12 ​ ​ 4 ​ ​ 27 ​ Financing cash flows from finance leases ​ ​ ​ ​ 127 ​ ​ 307 ​ ​ 312 ​ ​ 611 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ $ 7,327 ​ $ 549 ​ $ 7,490 ​ $ 4,081 ​
Schedule of future lease payments of operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases ​ Operating Leases ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 4,103 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 7,762 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 6,354 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,910 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,839 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,650 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 34,415 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 34 ​ ​ 70,033 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ (15,222) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 54,811 ​ ​
Schedule of future lease payments of finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases ​ Operating Leases ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 4,103 ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 7,762 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 6,354 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,910 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,839 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 5,650 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ 34,415 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 34 ​ ​ 70,033 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ (15,222) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 34 ​ $ 54,811 ​ ​ ​

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	6 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Accounts Receivable	The following is a summary of accounts receivable at March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ September 30, ​ ​ 2022 2021 Accounts receivable ​ $ 142,200 ​ $ 124,195 ​ Less allowance for expected credit losses ​ (4,622) ​ (4,318) ​ Accounts receivable, net ​ $ 137,578 ​ $ 119,877 ​
Summary of Inventories	The following is a summary of inventories at March 31, 2022 and September 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ September 30, ​ ​ 2022 2021 Inventories ​ ​ ​ Raw materials and purchased parts ​ $ 28,546 ​ $ 27,644 ​ Work-in-process ​ 5,885 ​ 4,787 ​ Finished goods ​ 43,321 ​ 27,967 ​ Total inventories ​ $ 77,752 ​ $ 60,398 ​
Product Warranty and Retrofit Activity on Gross Basis	The following is a summary of product warranty and retrofit activity on a gross basis for the three and six months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2022 Balance ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ Accruals ​ Costs Incurred ​ 2022 $ 2,342 ​ $ 539 ​ $ (390) ​ $ 2,491 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2021 Balance ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ March 31, 2020 ​ Accruals ​ Costs Incurred ​ 2021 $ 2,267 ​ $ 167 ​ $ (252) ​ $ 2,182 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2022 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ Accruals ​ Costs Incurred ​ 2022 $ 2,330 ​ $ 1,212 ​ $ (1,051) ​ $ 2,491 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2021 Balance ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ March 31, 2020 ​ Accruals ​ Costs Incurred ​ 2021 $ 2,211 ​ $ 813 ​ $ (842) ​ $ 2,182

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ 2022 2021 2022 2021 Restricted stock units ​ $ 8,058 ​ $ 7,048 ​ $ 15,255 ​ $ 13,192 ​ Employee stock purchase plan ​ 599 ​ 433 ​ 1,293 ​ 999 ​ Total stock-based compensation expense ​ $ 8,657 ​ $ 7,481 ​ $ 16,548 ​ $ 14,191 ​ ​
Restricted Stock Unit Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time-Based Stock Performance- ​ ​ Total Units ​ Units ​ Grants ​ Based Units Six months ended March 31, 2022 228,468 101,706 16,286 110,476 Six months ended March 31, 2021 329,801 ​ 149,249 14,657 165,895 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding at September 30, 2021 1,088,652 ​ $ 47.35 Granted 228,468 ​ ​ 103.31 Vested (208,713) ​ ​ 40.03 Forfeited (553,624) ​ ​ 39.30 Outstanding at March 31, 2022 554,783 ​ ​ 75.14

Earnings per Share (Tables)

Earnings per Share (Tables)	6 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Reconciliation of Weighted Average Common Shares Outstanding for Purposes of Calculating Basic and Diluted Earnings Per Share	The calculations of basic and diluted net income per share and basic and diluted weighted average shares outstanding are as follows for the three and six months ended March 31, 2022 and 2021 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2022 2021 2022 2021 (Loss) income from continuing operations ​ $ (1,816) ​ $ (7,336) ​ $ 1,041 ​ $ (4,630) ​ Income from discontinued operations, net of tax ​ 2,121,690 ​ 31,084 ​ 2,162,152 ​ 54,406 ​ Net income ​ $ 2,119,874 ​ $ 23,748 ​ $ 2,163,193 ​ $ 49,776 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic earnings per share ​ 74,958 ​ 74,265 ​ 74,823 ​ 74,142 ​ Dilutive restricted stock units ​ — ​ — ​ 322 ​ — ​ Weighted average common shares outstanding used in computing diluted earnings per share ​ 74,958 ​ 74,265 ​ 75,145 ​ 74,142 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income per share: ​ ​ ​ ​ ​ (Loss) income from continuing operations ​ $ (0.02) ​ $ (0.10) ​ $ 0.01 ​ $ (0.06) ​ Income from discontinued operations, net of tax ​ 28.31 ​ 0.42 ​ 28.90 ​ 0.73 ​ Basic net income per share ​ $ 28.28 ​ $ 0.32 ​ $ 28.91 ​ $ 0.67 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income per share: ​ ​ ​ ​ ​ (Loss) income from continuing operations ​ $ (0.02) ​ $ (0.10) ​ $ 0.01 ​ $ (0.06) ​ Income from discontinued operations, net of tax ​ 28.31 ​ 0.42 ​ 28.77 ​ 0.73 ​ Diluted net income per share ​ $ 28.28 ​ $ 0.32 ​ $ 28.79 ​ $ 0.67 ​

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue by Reporting Unit	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ Six months ended March 31, ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ ​ 2021 ​ Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 53,615 ​ $ 52,355 ​ $ 103,493 ​ $ 97,899 ​ Sample Repository Solutions ​ ​ ​ 26,929 ​ ​ 22,191 ​ ​ 52,805 ​ ​ 42,724 ​ Genomic Services ​ ​ ​ 65,000 ​ ​ 54,989 ​ ​ 128,898 ​ ​ 107,054 ​ Total ​ ​ $ 145,544 ​ $ 129,535 ​ $ 285,196 ​ $ 247,677 ​ ​
Remaining Performance Obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2022 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining Performance Obligations ​ $ 41,405 ​ $ 14,300 ​ $ 55,705 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Financial Information for Business Segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Revenue: ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 53,615 ​ $ 52,355 ​ ​ 103,487 ​ ​ 97,899 ​ Life Sciences Services ​ ​ 91,929 ​ 77,180 ​ 181,709 ​ 149,778 ​ Total revenue ​ ​ $ 145,544 ​ $ 129,535 ​ $ 285,196 ​ $ 247,677 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 5,288 ​ $ 7,248 ​ ​ 9,679 ​ ​ 11,431 ​ Life Sciences Services ​ ​ 4,856 ​ 5,614 ​ 12,740 ​ 12,542 ​ Reportable segment adjusted operating income ​ ​ ​ 10,144 ​ ​ 12,862 ​ ​ 22,419 ​ ​ 23,973 ​ Amortization of completed technology ​ ​ ​ 1,840 ​ ​ 2,021 ​ ​ 3,613 ​ ​ 4,026 ​ Amortization of other intangible assets ​ ​ ​ 6,047 ​ ​ 7,356 ​ ​ 12,319 ​ ​ 14,261 ​ Restructuring charges ​ ​ ​ 122 ​ ​ 92 ​ ​ 295 ​ ​ 53 ​ Tariff adjustment ​ ​ ​ (486) ​ ​ 5,497 ​ ​ (486) ​ ​ 5,497 ​ Other unallocated corporate expenses ​ ​ ​ 7,329 ​ ​ 7,216 ​ ​ 11,711 ​ ​ 9,101 ​ Total operating loss ​ ​ ​ (4,708) ​ ​ (9,320) ​ ​ (5,033) ​ ​ (8,965) ​ Interest income ​ ​ ​ 3,076 ​ ​ 18 ​ ​ 3,111 ​ ​ 94 ​ Interest expense ​ ​ ​ (1,555) ​ ​ (452) ​ ​ (2,010) ​ ​ (1,008) ​ Loss on extinguishment of debt ​ ​ ​ (632) ​ ​ — ​ ​ (632) ​ ​ — ​ Other income (expenses), net ​ ​ ​ (1,170) ​ ​ 108 ​ ​ (2,248) ​ ​ 1,389 ​ Loss before income taxes ​ ​ $ (4,989) ​ $ (9,646) ​ $ (6,812) ​ $ (8,490) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ Life Sciences Products ​ ​ Life Sciences Services ​ ​ Total ​ ​ ​ ​ March 31, 2022 ​ ​ $ 288,902 ​ $ 825,881 ​ $ 1,114,783 ​ ​ ​ ​ September 30, 2021 ​ ​ 278,769 ​ ​ 780,238 ​ 1,059,007 ​ ​ ​ ​ ​
Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2022 ​ 2021 Segment assets $ 1,114,783 $ 1,059,007 Cash and cash equivalents, restricted cash, and marketable securities ​ 3,025,685 ​ 244,012 Deferred tax assets ​ 1,816 ​ 10,043 Other assets ​ ​ 16,762 ​ ​ 11,237 Assets held for sale ​ — ​ 495,213 Total assets ​ $ 4,159,046 ​ $ 1,819,512
Revenue from External Customers Attributed to Geographic Areas	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ ​ Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ $ 94,283 ​ $ 79,753 ​ $ 184,366 ​ $ 153,302 ​ ​ Europe ​ ​ 26,554 ​ ​ 29,514 ​ ​ 55,149 ​ ​ 55,403 ​ ​ China ​ ​ 13,757 ​ ​ 11,736 ​ ​ 26,798 ​ ​ 22,791 ​ ​ Asia / Pacific/ Other ​ ​ 10,950 ​ ​ 8,532 ​ ​ 18,883 ​ ​ 16,181 ​ ​ Total ​ $ 145,544 ​ $ 129,535 ​ $ 285,196 ​ $ 247,677 ​ ​ ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ March 31, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2022 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 764,361 ​ $ 764,361 ​ $ — ​ $ — Available-for-sale securities ​ 1,076,732 ​ 517,457 ​ ​ 559,275 ​ — Foreign exchange contracts ​ 130 ​ — ​ 130 ​ — Net Investment Hedge ​ 10,673 ​ — ​ 10,673 ​ — Total Assets ​ $ 1,851,896 ​ $ 1,281,818 ​ $ 570,078 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 734 ​ ​ — ​ ​ 734 ​ ​ — Total Liabilities ​ $ 734 ​ $ — ​ $ 734 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ September 30, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2021 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 21 ​ $ 21 ​ $ — ​ $ — Available-for-sale securities ​ 3,679 ​ — ​ 3,679 ​ — Foreign exchange contracts ​ 153 ​ — ​ 153 ​ — Total Assets ​ $ 3,853 ​ $ 21 ​ $ 3,832 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ ​ 165 ​ $ — ​ ​ 165 ​ ​ — Acquisition-related contingent consideration ​ ​ 9,400 ​ ​ — ​ ​ — ​ ​ 9,400 Total Liabilities ​ $ 9,565 ​ $ — ​ $ 165 ​ $ 9,400 ​

Nature of Operation (Details)

Nature of Operation (Details) - Discontinued Operations, Disposed of by Sale - Semiconductor Automation Business $ in Billions	Feb. 01, 2022USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 2.9
Cash proceeds after adjustments and deducting taxes and other items	$ 2.5

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Foreign Currency Translation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Foreign Currency Transaction Gain (Loss), before Tax [Abstract]
Foreign currency transaction and remeasurement losses	$ (1,200)	$ (400)	$ (3,200)	$ 400
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]
Foreign currency translation reclassification adjustments included in income from discontinued operation	$ 16,567		$ 16,567

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [Abstract]
Realized losses on derivatives not designated as hedging instruments	$ 1,125	$ (5,173)	$ 1,054	$ (6,335)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Hedging Activities (Details) $ in Thousands, € in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2022USD ($)$ / €	Mar. 31, 2021USD ($)	Mar. 31, 2022USD ($)$ / €	Mar. 31, 2021USD ($)	Mar. 31, 2022EUR (€)$ / €
Derivative [Line Items]
Interest income	$ 3,076	$ 18	$ 3,111	$ 94
Currency Swap [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, notional amount, cross-currency swap, exchanged	1,030,000		1,030,000
Derivative, notional amount, cross-currency swap, received | €					€ 915
Derivative, notional amount	$ 960,000		$ 960,000
Derivative, fixed interest rate (as a percent)	1.283%		1.283%		1.283%
Derivative, notional amount, cross-currency swap, maturity, deliver | €					€ 852
Derivative, notional amount, cross-currency swap, maturity, receive	$ 960,000		$ 960,000
Derivative, forward exchange rate | $ / €	1.1261		1.1261		1.1261
Gain to accumulated other comprehensive income	$ 10,700		$ 10,700
Interest income	$ 2,100		$ 2,100
Currency Swap [Member] | Designated as Hedging Instrument [Member] | Weighted Average [Member]
Derivative [Line Items]
Derivative, variable interest rate	1.196%		1.196%		1.196%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details)	Mar. 31, 2022
Accounting Standards Update 2021-10
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2020-10
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021
Accounting Standards Update 2020-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2019-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021
Accounting Standards Update 2021-08
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021
Accounting Standards Update 2018-14
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 1, 2021

Discontinued Operations - Gener

Discontinued Operations - General Information (Details) $ in Thousands	Feb. 01, 2022USD ($)lease	Mar. 31, 2022USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Thomas H. Lee Partners, L.P.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transition service agreement, term, low end of range	3 months
Transition service agreement, term, high end of range	24 months
Sale leaseback transaction, lease agreements, number | lease	2
Sale leaseback transaction, lease term	24 months
Sale leaseback transaction, termination notice period	90 days
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 2,900,000
Cash proceeds after adjustments and deducting taxes and other items	2,500,000
Gain on divestiture		$ 2,561,420	$ 2,561,374
Liability related to retention and stock compensation for former employees of the Company that were conveyed with the transaction	$ 18,100
Discontinued Operations, Disposed of by Sale | Semiconductor Cryogenics Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net gain (loss) on sale				$ (1,300)

Discontinued Operations - Finan

Discontinued Operations - Financial Results (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net income from discontinued operations	$ 2,121,690	$ 31,084	$ 2,162,152	$ 54,406
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue	60,760	157,051	264,430	288,412
Total cost of revenue	36,418	87,677	152,324	163,245
Gross profit	24,342	69,374	112,106	125,167
Research and development	4,746	11,708	18,486	22,702
Selling, general and administrative	7,466	17,841	30,142	31,940
Restructuring charges		(1)		126
Total operating expenses	12,212	29,548	48,628	54,768
Operating income	12,130	39,826	63,478	70,399
Other income, net		(87)		(1,326)
Gain on divestiture	2,561,420		2,561,374
Income before income taxes	2,573,550	39,739	2,624,852	69,073
Income tax provision	451,860	8,655	462,700	14,667
Net income from discontinued operations	2,121,690	31,084	2,162,152	54,406
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Products
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue	56,722	144,136	244,962	262,290
Total cost of revenue	33,568	82,727	141,165	151,504
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Services
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue	4,038	12,915	19,468	26,122
Total cost of revenue	$ 2,850	$ 4,950	$ 11,159	$ 11,741

Discontinued Operations - Non-c

Discontinued Operations - Non-cash Items and Capital Expenditures (Details) - Discontinued Operations, Disposed of by Sale - Semiconductor Automation Business - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2022	Mar. 31, 2021
Discontinued Operation, Alternative Cash Flow Information [Abstract]
Depreciation and amortization		$ 1,677		$ 3,696
Capital expenditures	$ 579	904	$ 2,862	2,731
Stock-based compensation	$ 3,109	$ 4,088	$ 8,032	$ 5,963

Discontinued Operations - Asset

Discontinued Operations - Assets and Liabilities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Cash and cash equivalents	$ 45,000
Total current assets of discontinued operation	311,385
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Total long-term assets of discontinued operation	183,828
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Total current liabilities of discontinued operation	128,939
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Total long-term liabilities of discontinued operation	32,444
Discontinued Operations, Held-for-sale | Semiconductor Automation Business
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Cash and cash equivalents	45,000
Accounts receivable, net	142,256
Inventories	110,735
Other current assets	13,394
Total current assets of discontinued operation	311,385
Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]
Property, plant and equipment, net	32,058
Long-term deferred tax assets	3,167
Goodwill	81,477
Intangibles, net	44,468
Other assets	22,658
Total long-term assets of discontinued operation	183,828
Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]
Accounts payable	68,074
Deferred revenue	7,141
Accrued warranty and retrofit costs	6,081
Accrued compensation and benefits	18,144
Accrued Income Taxes	11,702
Accrued expenses and other current liabilities	18,014
Total current liabilities of discontinued operation	129,156
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]
Long-term tax reserves	2,356
Long-term deferred tax liabilities	6,548
Long-term pension liabilities	5,490
Long-term operating lease liabilities	15,425
Other long-term liabilities	2,625
Total long-term liabilities of discontinued operation	$ 32,444

Discontinued Operations - Acqui

Discontinued Operations - Acquisitions (Details) - USD ($) $ in Thousands	Apr. 29, 2021	Mar. 31, 2022	Mar. 31, 2022	Sep. 30, 2021
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill		$ 467,746	$ 467,746	$ 469,356
Payments to Acquire Productive Assets [Abstract]
Purchases of technology intangibles			$ 4,000
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Precise Automation, Inc.
Business Acquisition, Date of Acquisition [Abstract]
Business acquisition, effective date of acquisition	Apr. 29, 2021
Business Combination, Consideration Transferred [Abstract]
Total purchase price	$ 69,800
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	33,100
Deferred tax liabilities	$ 6,200
Weighted average useful life of intangible assets	11 years
Business combination, option to purchase certain technology assets, exercised		4,000
Business Combination, Goodwill [Abstract]
Goodwill deductible for tax purposes	$ 0
Payments to Acquire Productive Assets [Abstract]
Purchases of technology intangibles		$ 4,000
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Precise Automation, Inc. | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	38,700
Discontinued Operations, Held-for-sale | Semiconductor Automation Business | Precise Automation, Inc. | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets	$ 2,500

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 1,080,028	$ 3,679
Gross Unrealized Losses	(3,314)
Gross Unrealized Gains	18
Fair Value	1,076,732	3,679
U.S. Treasury securities and obligations of U.S. government agencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	720,648
Gross Unrealized Losses	(1,185)
Gross Unrealized Gains	18
Fair Value	719,481
Certificates of Deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		30
Fair Value		30
Corporate securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	258,862	3,624
Gross Unrealized Losses	(1,899)
Fair Value	256,963	3,624
Municipal securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	100,518
Gross Unrealized Losses	(230)
Fair Value	$ 100,288
Other debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		25
Fair Value		$ 25

Marketable Securities - Fair Va

Marketable Securities - Fair Value of Marketable Securities by Contractual Maturity (Details) $ in Thousands	Mar. 31, 2022USD ($)
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
Amortized cost, due in one year or less	$ 817,223
Amortized cost, due in one year	0
Amortized cost, due after one year through five years	259,382
Amortized cost, due after ten years	3,422
Amortized cost	1,080,027
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Fair value, due in one year or less	816,512
Fair value, due in one year	0
Fair value, due after one year through five years	256,797
Fair value, due after ten years	3,423
Fair value	$ 1,076,732

Marketable Securities - Unreali

Marketable Securities - Unrealized Loss Position (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Debt Securities, Available-for-sale, Unrealized Loss Position [Abstract]
Fair value of marketable securities in unrealized loss position	$ 939,100	$ 0

Acquisitions - General Informat

Acquisitions - General Information (Details)	Apr. 02, 2021	Dec. 03, 2020
Abeyatech LLC
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition	Apr. 2, 2021
Trans-Hit Biomarkers
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition		Dec. 3, 2020

Acquisitions - Purchase Conside

Acquisitions - Purchase Consideration (Details) - USD ($) $ in Millions	Apr. 02, 2021	Dec. 03, 2020
Abeyatech LLC
Business Acquisition [Line Items]
Net cash outflow	$ 9.9
Acquisition-related contingent consideration	$ 9.4
Trans-Hit Biomarkers
Business Acquisition [Line Items]
Total purchase price		$ 15.1

Acquisitions - Contingent Consi

Acquisitions - Contingent Consideration Paid (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2022
Business Acquisition [Line Items]
Payment for contingent consideration related to acquisition, financing activities		$ 9,400
Abeyatech LLC
Business Acquisition [Line Items]
Payment for contingent consideration related to acquisition	$ 10,000

Acquisitions - Amounts of Asset

Acquisitions - Amounts of Assets and Liabilities at Fair Value as of Acquisition Date (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021	Apr. 02, 2021	Dec. 03, 2020
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 467,746	$ 469,356
Abeyatech LLC
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill			$ 4,400
Intangible assets			11,900
Other assets and liabilities, net			$ 3,000
Trans-Hit Biomarkers
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill				$ 9,300
Intangible assets				7,800
Long-term deferred tax liabilities				$ (2,400)

Acquisitions - Intangible Asset

Acquisitions - Intangible Assets Acquired (Details)	Apr. 02, 2021	Dec. 03, 2020
Abeyatech LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	12 years
Trans-Hit Biomarkers
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		11 years

Acquisitions - Goodwill (Detail

Acquisitions - Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021	Apr. 02, 2021	Dec. 03, 2020
Business Combination, Goodwill [Abstract]
Goodwill	$ 467,746	$ 469,356
Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill	108,495	110,138
Life Sciences Services
Business Combination, Goodwill [Abstract]
Goodwill	$ 359,251	$ 359,218
Abeyatech LLC
Business Combination, Goodwill [Abstract]
Goodwill			$ 4,400
Abeyatech LLC | Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill deductible for tax purposes			$ 4,400
Trans-Hit Biomarkers
Business Combination, Goodwill [Abstract]
Goodwill				$ 9,300
Trans-Hit Biomarkers | Life Sciences Services
Business Combination, Goodwill [Abstract]
Goodwill deductible for tax purposes				$ 0

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill Roll Forward (Details) $ in Thousands	6 Months Ended
	Mar. 31, 2022USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 469,356
Goodwill, ending balance	467,746
Life Sciences Products
Goodwill [Roll Forward]
Goodwill, beginning balance	110,138
Currency translation adjustments	(1,643)
Goodwill, ending balance	108,495
Life Sciences Services
Goodwill [Roll Forward]
Goodwill, beginning balance	359,218
Currency translation adjustments	33
Goodwill, ending balance	359,251
Other
Goodwill [Roll Forward]
Goodwill, beginning balance	469,356
Currency translation adjustments	(1,610)
Goodwill, ending balance	$ 467,746

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Cost	$ 331,015	$ 331,606
Accumulated Amortization	160,508	145,072
Net Book Value	170,507	186,534
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	1,234	1,242
Accumulated Amortization	1,055	1,002
Net Book Value	179	240
Completed Technology
Finite-Lived Intangible Assets [Line Items]
Cost	75,373	75,527
Accumulated Amortization	35,833	32,383
Net Book Value	39,540	43,144
Trademarks and Trade Names
Finite-Lived Intangible Assets [Line Items]
Cost	424	424
Accumulated Amortization	47	33
Net Book Value	377	391
Noncompete Agreements
Finite-Lived Intangible Assets [Line Items]
Cost	681	681
Accumulated Amortization	344	249
Net Book Value	337	432
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Cost	253,063	253,486
Accumulated Amortization	122,989	111,159
Net Book Value	130,074	142,327
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Cost	240	246
Accumulated Amortization	$ 240	$ 246

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 7.9	$ 9.4	$ 15.9	$ 18.3

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022	$ 15,937
2023	30,845
2024	27,354
2025	22,574
2026	19,435
Thereafter	54,362
Net Book Value	$ 170,507	$ 186,534

Debt and Line of Credit (Detail

Debt and Line of Credit (Details) - USD ($) $ in Thousands	Feb. 01, 2022	Mar. 31, 2022	Mar. 31, 2022	Oct. 04, 2017
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 632	$ 632
Secured Debt | Senior Secured Term Loan Facility
Debt Instrument [Line Items]
Face amount				$ 200,000
Issue amount				$ 197,600
Percentage of par (as a percent)				98.80%
Discount				$ 2,400
Discount percentage (as a percent)				1.20%
Weighted average interest rate (as a percent)			2.70%
Interest expense		100	$ 500
Deferred financing costs amortization		$ 100	$ 100
Debt extinguished	$ 49,700
Loss on extinguishment of debt	$ 600

Leases - Lease Expense (Details

Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Lease, Cost [Abstract]
Operating lease costs	$ 2,389	$ 1,740	$ 4,560	$ 3,444
Amortization of assets	54	250	129	561
Interest on lease liabilities	2	6	5	23
Total finance lease costs	56	256	134	584
Variable lease cost	755	457	1,272	863
Short-term lease costs	364	50	718	89
Total lease costs	$ 3,564	$ 2,503	$ 6,684	$ 4,980

Leases - Assets and Liabilities

Leases - Assets and Liabilities - Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Assets and Liabilities, Lessee [Abstract]
Operating lease right-of-use assets	$ 53,278	$ 49,650
Accrued expenses and other current liabilities	$ 6,113	$ 5,254
Operating Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Long-term operating lease liabilities	$ 48,698	$ 45,088
Total lease liability balance	$ 54,811	$ 50,342

Leases - Assets and Liabiliti_2

Leases - Assets and Liabilities - Finance Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]
Property, plant and equipment, at cost	$ 2,252	$ 2,252
Accumulated amortization	(2,234)	(2,105)
Property, plant and equipment, net	$ 18	$ 147
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease Liability [Abstract]
Accrued expenses and other current liabilities	$ 44	$ 360
Finance Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Other long-term liabilities, net	$ (10)	$ (10)
Total finance lease liabilities	$ 34	$ 350

Leases - Additional Information

Leases - Additional Information (Details)	Mar. 31, 2022	Sep. 30, 2021
Leases [Abstract]
Weighted average remaining lease term, operating leases	11 years 8 months 26 days	11 years 3 months 29 days
Weighted average remaining lease term, finance leases	29 days	6 months 10 days
Weighted average discount rate, operating leases (as a percent)	4.05%	3.90%
Weighted average discount rate, finance leases (as a percent)	4.86%	4.87%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 1,950	$ 1,548	$ 3,599	$ 2,968
Operating cash flows from finance leases	1	12	4	27
Financing cash flows from finance leases	$ 127	$ 307	$ 312	$ 611

Leases - Assets Obtained in Exc

Leases - Assets Obtained in Exchange for Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
ROU assets obtained in exchange for lease liabilities, operating leases	$ 7,327	$ 549	$ 7,490	$ 4,081

Leases - Future Lease Payments

Leases - Future Lease Payments - Operating Leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 4,103
2023	7,762
2024	6,354
2025	5,910
2026	5,839
2027	5,650
Thereafter	34,415
Total future lease payments	$ 70,033

Leases - Gross Difference - Ope

Leases - Gross Difference - Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total future lease payments	$ 70,033
Less imputed interest	(15,222)
Total lease liability balance	$ 54,811	$ 50,342

Leases - Future Lease Payment_2

Leases - Future Lease Payments - Finance Leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Finance Lease, Liability, Payment, Due [Abstract]
2022	$ 34
Total future lease payments	$ 34

Leases - Gross Difference - Fin

Leases - Gross Difference - Finance Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Finance Lease Liabilities, Gross Difference, Amount [Abstract]
Total future lease payments	$ 34
Total finance lease liabilities	$ 34	$ 350

Income Taxes - Provision (Benef

Income Taxes - Provision (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense (benefit)	$ (3,173)	$ (2,310)	$ (7,853)	$ (3,860)
Benefit related to stock compensation windfalls			4,500	$ 2,000
Charge to increase the deferred tax liability to reflect a change in the blended state income tax rate that results from the sale of the semiconductor business assets			$ 600

Income Taxes - Valuation Allowa

Income Taxes - Valuation Allowance (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Utilization of Previously Expected to Expire Deferred Tax Assets, Driven by Income from Discontinued Operations
Valuation Allowance [Line Items]
Decrease in valuation allowance	$ 3.6

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits - Interest Expense (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2022
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]
Interest related to unrecognized benefits	$ 0.1	$ 0.1

Income Taxes - Unrecognized T_2

Income Taxes - Unrecognized Tax Benefits - Decrease in Unrecognized Tax Benefits is Reasonably Possible (Details) $ in Millions	Mar. 31, 2022USD ($)
Income Tax Disclosure [Abstract]
Anticipated unrecognized tax benefit reduction during next twelve months	$ 0.4

Other Balance Sheet Informati_3

Other Balance Sheet Information - Summary of Account Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable	$ 142,200	$ 124,195
Less allowance for expected credit losses	(4,622)	(4,318)
Accounts receivable, net	$ 137,578	$ 119,877

Other Balance Sheet Informati_4

Other Balance Sheet Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials and purchased parts	$ 28,546	$ 27,644
Work-in-process	5,885	4,787
Finished goods	43,321	27,967
Inventory, net	77,752	60,398
Reserves for excess and obsolete inventory	$ 4,400	$ 3,700

Other Balance Sheet Informati_5

Other Balance Sheet Information - Capitalized Direct Costs (Details) - USD ($) $ in Millions	6 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 24.2	$ 22.7
Capitalized computer software costs	1.6
Software Development
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 6.3

Other Balance Sheet Informati_6

Other Balance Sheet Information - Product Warranty and Retrofit Activity on Gross Basis (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning Balance	$ 2,342	$ 2,267	$ 2,330	$ 2,211
Accruals for warranties	539	167	1,212	813
Costs incurred	(390)	(252)	(1,051)	(842)
Ending Balance	$ 2,491	$ 2,182	$ 2,491	$ 2,182

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 8,657	$ 7,481	$ 16,548	$ 14,191
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	8,058	7,048	15,255	13,192
Restricted Stock Units (RSUs) | Continuing Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	5,200	3,200	7,700	7,700
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	599	433	1,293	999
Employee Stock | Continuing Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 400	$ 200	$ 800	$ 500

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Granted - Tabular Disclosure (Details) - shares	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	228,468	329,801
Restricted Stock, Time Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	101,706	149,249
Board of Director Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	16,286	14,657
Restricted Stock, Performance Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	110,476	165,895

Stock-Based Compensation - Time

Stock-Based Compensation - Time-Based Restricted Stock Unit Grants (Details) - Restricted Stock, Time Based Shares	6 Months Ended
	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-based Compensation Award, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance-Based Restricted Stock Unit Grants (Details)	6 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Performance-based awards granted, percentage (as a percent)	100.00%	100.00%	100.00%
Performance-based awards granted, percentage, maximum threshold met (as a percent)	200.00%	200.00%	200.00%
Performance goal measurement period (in years)	3 years

Stock-Based Compensation - Re_2

Stock-Based Compensation - Restricted Stock Unit Activity - Tabular Disclosure (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Shares
Outstanding at beginning of period (in shares)			1,088,652
Restricted stocks granted (in shares)			228,468	329,801
Vested (in shares)			(208,713)
Forfeited (in shares)			(553,624)
Outstanding at end of period (in shares)	554,783		554,783
Weighted Average Grant-Date Fair Value
Outstanding at beginning of period (in dollars per share)			$ 47.35
Granted (in dollars per share)	$ 82.34	$ 80.09	103.31	$ 70.18
Vested (in dollars per share)			40.03
Forfeited (in dollars per share)			39.30
Outstanding at end of period (in dollars per share)	$ 75.14		$ 75.14

Stock-Based Compensation - Re_3

Stock-Based Compensation - Restricted Stock Unit Activity - Additional Information (Details) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)	$ 82.34	$ 80.09	$ 103.31	$ 70.18
Fair value of restricted stock awards vested	$ 1.9	$ 2	$ 66.7	$ 27.9
Proceeds from employees to satisfy tax obligation			$ 25.1	$ 9.7

Stock-Based Compensation - Re_4

Stock-Based Compensation - Restricted Stock Unit Activity - Unrecognized Compensation Cost (Details) - Restricted Stock Units (RSUs) $ in Millions	6 Months Ended
	Mar. 31, 2022USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 29
Unrecognized compensation cost, estimated weighted average amortization period	1 year 10 months 24 days

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - shares	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued under employee stock purchase plan (in shares)	51,133	58,124
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock (as a percent)	85.00%

Earnings per Share - Tabular Di

Earnings per Share - Tabular Disclosure (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Net income
(Loss) income from continuing operations	$ (1,816)	$ (7,336)	$ 1,041	$ (4,630)
Income from discontinued operations, net of tax	2,121,690	31,084	2,162,152	54,406
Net income	2,119,874	23,748	2,163,193	49,776
Net income attributable to Brooks Automation, Inc. - basic	2,119,874	23,748	2,163,193	49,776
Net income attributable to Brooks Automation, Inc. - diluted	$ 2,119,874	$ 23,748	$ 2,163,193	$ 49,776
Weighted average common shares outstanding used in computing diluted earnings per share
Weighted average common shares outstanding used in computing basic earnings per share (in shares)	74,958	74,265	74,823	74,142
Dilutive restricted stock units			322
Weighted average common shares outstanding used in computing diluted earnings per share (in shares)	74,958	74,265	75,145	74,142
Basic net income per share:
(Loss) income from continuing operations (in dollars per share)	$ (0.02)	$ (0.10)	$ 0.01	$ (0.06)
Income from discontinued operations, net of tax (in dollars per share)	28.31	0.42	28.90	0.73
Basic net income per share (in dollars per share)	28.28	0.32	28.91	0.67
Diluted net income per share:
(Loss) income from continuing operations (in dollars per share)	(0.02)	(0.10)	0.01	(0.06)
Income from discontinued operations, net of tax (in dollars per share)	28.31	0.42	28.77	0.73
Diluted net income per share (in dollars per share)	$ 28.28	$ 0.32	$ 28.79	$ 0.67

Earnings per Share - Anti-dilut

Earnings per Share - Anti-dilutive Securities (Details)	6 Months Ended
	Mar. 31, 2022shares
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted earnings per share (in shares)	59,513

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregated By Reporting Unit (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 145,544	$ 129,535	$ 285,196	$ 247,677
Life Sciences Products
Disaggregation of Revenue [Line Items]
Total revenue	$ 53,615	$ 52,355	$ 103,493	$ 97,899
Reporting unit, name of segment	Life Sciences Products	Life Sciences Products	Life Sciences Products	Life Sciences Products
Sample Repository Solutions
Disaggregation of Revenue [Line Items]
Total revenue	$ 26,929	$ 22,191	$ 52,805	$ 42,724
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services	Life Sciences Services	Life Sciences Services
Genomic Services
Disaggregation of Revenue [Line Items]
Total revenue	$ 65,000	$ 54,989	$ 128,898	$ 107,054
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services	Life Sciences Services	Life Sciences Services

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net of allowance for expected credit losses ($4,622 and $4,318, respectively)	$ 137,578	$ 119,877
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Contract assets	25,800	15,300
Contract with Customer, Liability [Abstract]
Current contract liabilities	30,700	25,724
Contract liabilities	30,700	$ 25,700
Revenue recognized	$ 18,200

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Remaining Performance Obligations (Details) $ in Thousands	Mar. 31, 2022USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 55,705
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 41,405
Unsatisfied performance obligation, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 14,300
Unsatisfied performance obligation, period

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Costs to Obtain and Fulfill a Contract (Details)	Mar. 31, 2022
Capitalized Contract Cost [Abstract]
Sales commission amortization period	60 months

Segment and Geographic Inform_3

Segment and Geographic Information - General Information (Details) - segment	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2	2	2
Number of operating segments	2	2	2	2
Number of reportable segments, previously operated	3	3	3	3

Segment and Geographic Inform_4

Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Total revenue	$ 145,544	$ 129,535	$ 285,196	$ 247,677
Amortization of other intangible assets	7,900	9,400	15,900	18,300
Restructuring charges	122	92	295	53
Tariff adjustment	(486)	5,497	(486)	5,497
Operating income (loss)	(4,708)	(9,320)	(5,033)	(8,965)
Interest income	3,076	18	3,111	94
Interest expense	(1,555)	(452)	(2,010)	(1,008)
Loss on extinguishment of debt	(632)		(632)
Other income (expenses), net	(1,170)	108	(2,248)	1,389
(Loss) income before income taxes	(4,989)	(9,646)	(6,812)	(8,490)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	1,840	2,021	3,613	4,026
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	6,047	7,356	12,319	14,261
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	53,615	52,355	103,487	97,899
Operating income (loss)	5,288	7,248	9,679	11,431
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	91,929	77,180	181,709	149,778
Operating income (loss)	4,856	5,614	12,740	12,542
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	145,544	129,535	285,196	247,677
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating income (loss)	10,144	12,862	22,419	23,973
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense (income)	$ 7,329	$ 7,216	$ 11,711	$ 9,101

Segment and Geographic Inform_5

Segment and Geographic Information - Financial Information for Business Segments - Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total assets	$ 4,159,046	$ 1,819,512
Operating Segments
Segment Reporting Information [Line Items]
Total assets	1,114,783	1,059,007
Operating Segments | Life Sciences Products
Segment Reporting Information [Line Items]
Total assets	288,902	278,769
Operating Segments | Life Sciences Services
Segment Reporting Information [Line Items]
Total assets	$ 825,881	$ 780,238

Segment and Geographic Inform_6

Segment and Geographic Information - Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Cash and cash equivalents, restricted cash, and marketable securities	$ 3,025,685	$ 244,012
Deferred tax asset	1,816	10,043
Other assets	16,762	11,237
Assets held for sale		495,213
Assets	4,159,046	1,819,512
Operating Segments
Segment Reporting Information [Line Items]
Assets	$ 1,114,783	$ 1,059,007

Segment and Geographic Inform_7

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Tabular Disclosure (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 145,544	$ 129,535	$ 285,196	$ 247,677
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	94,283	79,753	184,366	153,302
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	26,554	29,514	55,149	55,403
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	13,757	11,736	26,798	22,791
Asia / Pacific/ Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 10,950	$ 8,532	$ 18,883	$ 16,181

Segment and Geographic Inform_8

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk, North America [Member] | UNITED STATES
Concentration Risk [Line Items]
Concentration risk (as a percent)	99.00%	99.00%

Commitments and Contingencies -

Commitments and Contingencies - Tariff Matter (Details) - Tariffs - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	May 06, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual		$ 7.4	$ 7	$ 6.1
Loss contingency benefit		$ 0.5
Subsequent Event
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency payment	$ 5.9

Commitments and Contingencies_2

Commitments and Contingencies - Purchase Commitments (Details) $ in Millions	Mar. 31, 2022USD ($)
Non-cancelable commitments
Other Commitments [Line Items]
Other commitment	$ 97
Non-cancellable Contracts and Purchase Orders for Inventory
Other Commitments [Line Items]
Other commitment	76.7
Non-cancelable IT-related commitments
Other Commitments [Line Items]
Other commitment	16.7
Non-cancelable China facility commitments
Other Commitments [Line Items]
Other commitment	$ 3.6

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Sep. 30, 2021
Assets:
Available-for-sale securities	$ 1,076,732	$ 3,679
Fair Value, Measurements, Recurring
Assets:
Available-for-sale securities	1,076,732	3,679
Foreign exchange contracts	130	153
Net Investment Hedge	10,673
Total Assets	1,851,896	3,853
Liabilities:
Foreign exchange contracts	734	165
Acquisition-related contingent consideration		9,400
Total Liabilities	734	9,565
Fair Value, Measurements, Recurring | Cash equivalents
Assets:
Cash equivalents	764,361	21
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring
Assets:
Available-for-sale securities	517,457
Total Assets	1,281,818	21
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Cash equivalents
Assets:
Cash equivalents	764,361	21
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring
Assets:
Available-for-sale securities	559,275	3,679
Foreign exchange contracts	130	153
Net Investment Hedge	10,673
Total Assets	570,078	3,832
Liabilities:
Foreign exchange contracts	734	165
Total Liabilities	$ 734	165
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Liabilities:
Acquisition-related contingent consideration		9,400
Total Liabilities		$ 9,400